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A B S T R A C T   
Hypertrophic cardiomyopathy (HCM) is the commonest genetic cardiac disease, with a prevalence of 1/500. It is 
caused by over 1400 different mutations, mainly involving the genes coding for sarcomere proteins. The main 
pathological features of HCM are left ventricular hypertrophy, diastolic dysfunction and the increased ventricular 
arrhythmogenesis. Predicting the risk of heart failure and lethal arrhythmias is the most challenging clinical task 
for HCM patient management. Moreover, there are no disease-modifying therapies that can prevent disease 
progression or sudden arrhythmic death in HCM patients. In this review, we will illustrate the most advanced 
research models and methods that have been employed for HCM studies, including preclinical tests of novel or 
existing drugs, along with visionary future development based on gene editing approaches. Acknowledging the 
advantages and limitations of the different models, and a critical consideration of the different, often conflicting 
result obtained using different approaches is essential for a deep understanding of HCM pathophysiology and for 
obtaining meaningful information on novel treatments, in order to improve patient risk stratification and 
therapeutic management.   
1. Hypertrophic cardiomyopathy: general features 
Hypertrophic cardiomyopathy (HCM) is the commonest inherited 
monogenic cardiac disorder, having a prevalence of one out of 500 in 
different population cohorts [1,2]. HCM represents a significant cause of 
sudden death due to ventricular arrhythmias, and is associated with 
heart failure and atrial fibrillation [1,2]. It has a worldwide distribution, 
as cases were observed in over 50 countries on all continents [2], and it 
indistinctly affects males and females [3], as well as subjects of various 
ethnic origins, with similar clinical course and phenotypic expression 
[2–4]. 
Despite a wide variability in the individual pathological features, the 
hallmark of HCM is represented by left ventricular hypertrophy [1], 
often asymmetrically distributed, generally involving the anterior basal 
septum and the anterolateral free wall [5] (Fig.1); in some patients, 
hypertrophy can be confined to the apex and in a small minority of them, 
it can be widespread and symmetrically distributed. The appearance of 
left ventricular hypertrophy can be usually observed at puberty or early 
adulthood, but the onset of the hypertrophic condition varies, 
potentially manifesting at birth, during childhood, or developing as late 
as the 6th decade of life. The burden of left ventricular hypertrophy 
depends on the thickness of the left ventricular wall: indeed, absolute 
left-ventricular wall thickness values can vary from mild (13− 15 mm) to 
severe (above 30 mm), with an average of 21–23 mm in different HCM 
patient cohorts [6,7]. Disease course can be benign, stable, with mild or 
no symptoms in a significant percentage of patients. Approximately 65 
% of HCM patients display symptomatic obstruction of the LV outflow 
tract at some point during their life, half of them experiencing symptoms 
only during stress or exercise (inducible obstruction) and the other half 
with symptoms that are present also at rest [8–10] Obstruction is asso-
ciated with significant repercussions on prognosis, with significantly 
increased mortality if untreated [11]. 
In about 15 % of HCM patients, LV mechanical function starts 
deteriorating toward systolic dysfunction (hypokinetic progression) or 
to a severe worsening of LV diastolic function (restrictive progression) 
[10]. In about one fourth of patients with adverse progression (4% of 
total patients), end-stage disease develops, leading to terminal heart 
failure, often requiring transplantation [9,12]. However, the most 
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unpredictable and devastating consequence of HCM is represented by 
arrhythmic sudden death (SD), most commonly induced by sustained 
ventricular tachycardia (VT), subsequently followed by ventricular 
fibrillation (VF). Indeed, HCM is a leading cause of arrhythmic sudden 
death in young population (under the age of 45), with a marked pref-
erence for youngster and young adults (age <30 years) [13–15]. The risk 
of SD is higher in patients where the onset of left ventricular hypertro-
phy occurs during childhood (pediatric HCM) [16]. SD may occur at any 
age, and the risk of lethal arrhythmias continues to be present through 
the whole life, although the average annual risk of SD is relatively low 
(0.3− 0.5% per year) [17]. Moreover, SD in HCM patients is considerably 
less usual in subjects over 60 years of age, suggesting that in HCM the 
likelihood of lethal VT is reduced by ageing [15]. 
1.1. Genetics 
Over 1400 autosomal mutations, transmitted in a dominant pattern, 
have been identified in 11 genes encoding proteins of the thick and thin 
filament of the sarcomere, or the components of the adjacent Z-discs 
[18–23]. Most of HCM-causing mutations are unique to individual 
families, suggesting that this pathological condition is characterized by a 
high genotype variability. Among the patients characterized by HCM 
pathogenic mutations, about 70 % have mutations either in the β-myosin 
heavy chain gene (MYH7) or in the myosin binding protein C gene 
(MYBPC3). Mutations in Troponin T (TNNT2), cardiac Troponin I 
(TNNI3) and α tropomyosin (TPMI) genes assess for about 5 % of cases 
each [18–23]. Considering the major improvement of the genetic testing 
in HCM observed in the recent years, Burns and coworkers aimed to 
study the prevalence of multiple variant genotypes in HCM, evaluating 
their clinical impact through targeted gene panel tools. To this aim, 758 
probands diagnosed for HCM were screened for specific variants 
through sized gene panels, revealing that multiple variants identified in 
HCM genes are related to earlier disease onset and worsen survival of 
HCM patients from major cardiovascular events. In particular, the au-
thors of this study suggest to focus HCM genetic testing on the 8 major 
HCM genes (ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, 
TPM1), also extending the screening to additional phenocopy genes as 
PRKAG2, LAMP2, GLA, and PLN [24]. Despite the current advancements 
in cardiogenetics and the introduction of modern next-generation 
sequencing techniques, about 40 % of all HCM cases remain unex-
plained [25,26], suggesting oligogenic or polygenic mechanisms. 
Genotype-to-phenotype correlations in HCM are made difficult by the 
incomplete penetrance of several mutations and by the intrinsic vari-
ability of disease presentation, severity and progression, even among 
different components of the same family presenting the same pathologic 
variant. 
Early studies on large families with a severe disease presentation and 
high penetrance led to the identification of “high-risk” mutations, such 
as MYH7-R403Q and R453C [27] and TNNT2-R92Q/W [28]. Studies on 
larger unrelated populations partially confirmed the malignant nature of 
five early-identified “high-risk” mutations (MYH7-R403Q, 
MYH7-R453C, MYH7-G716R, MYH7-R719W and TNNT2-R92W) [19] 
and showed a large variability of outcome among patients carrying the 
same mutations. Recent studies demonstrated that pathological variants 
in the genes coding for thin-filament proteins (TNNT2, TNNI3, ACTC) 
are correlated with an higher risk of sudden death during childhood [16] 
and an increased probability of adverse disease progression during 
adulthood [29], as compared with the more common thick-filament 
gene mutations. Despite these differences in outcome between patients 
carrying thick and thin filament mutations, recent studies on larger HCM 
populations confirmed that different mutations, even within the same 
gene, are associated with different disease severity, and confirmed that 
certain “high-risk” variants (e.g. mutations of the converter region of 
MYH7) are linked with a higher likelihood of SD [30,31]. Finally, pa-
tients carrying two or more different disease-causing variants in sarco-
meric genes have a higher likelihood of lethal arrhythmias and adverse 
disease progression [32,33]. 
1.2. Non-genetic factors 
Genetic and non-genetic factors concur to drive the evolution of the 
pathogenesis of HCM. The phenotypic variability among patients is the 
end-result of many factors that include oxidative stress, inflammation, 
apoptosis and dysfunctional regulatory pathways such as autophagy 
[34,35]. A deeper comprehension of the dysfunctional mechanism 
involved in HCM pathogenesis is of utmost relevance, especially from a 
pharmacological perspective. In particular, a crucial role is played by 
the disproportional energetic demand in HCM [34,35], mitochondrial 
workload and Reactive oxygen species (ROS) formation. Oxidative stress 
is a condition characterized by a disproportion between the generation 
and the neutralization of reactive oxygen species (ROS). The occurrence 
of oxidative stress in human samples from explanted failing hearts 
(where the failure is secondary to several cardiomyopathies) [36–38] 
and its involvement in the pathogenesis of heart failure (HF) was pre-
viously reported [39]. Despite scarce information available on the role 
of oxidative stress in HCM, some evidence in the literature suggests the 
presence of ROS overproduction in HCM myocardium, causing protein 
alterations, lipid peroxidation and DNA damage, contributing to cell 
Fig. 1. Human samples for HCM modeling and drug screening.  
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death [40,41]. A confirmation of the role of oxidative stress in HCM 
pathogenesis was provided by Dimitrow and coworkers, who observed 
increased serum levels of 8-iso-prostaglandin F2α in a selected group of 
patients affected by HCM, compared to healthy controls (35.4 ± 10.2 vs. 
29.9 ± 9.9 pg/mL, p < 0.001). Moreover, there was a correlation be-
tween the obstructive form of the disease and an elevation of oxidative 
stress by-products, indicative of oxidative stress as an important player 
in the development of the hypertrophic burden in HCM [40]: indeed, 
8-iso-prostaglandin F2α was particularly high in HCM patients with LV 
outflow obstruction (41.6 ± 12.7 vs. 31.4 ± 5.4 pg/mL in HCM patients 
without obstruction, p < 0.0001). Oxidative stress may be also one of the 
triggers of low-grade inflammation, feature of the early phase of the 
development of HCM, and of fibrosis, associated with worse clinical 
outcomes, through activation of specific signaling pathways [42]. In the 
heart, ROS also impairs autophagy, i.e., the quality control mechanisms 
of proteins and nucleic acids, consequently causing senescence and 
apoptosis [43,44]. The role of autophagy in the maintenance of cardiac 
homeostasis under stressing pathophysiological conditions has been 
extensively explored, and several cardiac disorders — including HCM — 
are indeed characterized by defective autophagy [45,46]. 
In the last 15 years, the comprehension of HCM patho-mechanisms is 
consistently improved. This advance in HCM research was made 
possible by the use of different tools for cardiovascular pathologies 
modeling, such as human samples and different type of animal models. 
However, the development of iPSC technique represents the turning 
point for modeling and studying inherited cardiac pathologies, 
including HCM. In fact, compared to other research approaches, iPSC 
method is able to supply a potentially unlimited amount of cells, also 
preserving the genetic background of the patients, consequently over-
coming difficulties and limitations that are intrinsic flaws of other study 
models. 
2. Research models to study the pathophysiology of HCM 
2.1. Studies in human samples reveal multiple therapeutic targets 
Living cardiomyocytes isolated from fresh human cardiac samples 
are very informative to gain deeper insights into the specific patho- 
mechanisms of cardiomyopathies in vitro (Table 1). We recently inves-
tigated the electromechanical features of cardiac myocytes isolated from 
ventricular samples from HCM patients undergoing surgical septal 
myectomy due severe LV outflow tract obstruction [47,48]. We per-
formed ion fluorescence and patch-clamp experiments to evaluate the 
electrophysiological abnormalities characterizing the pathogenesis of 
HCM, by comparing the functional properties of cardiomyocytes iso-
lated from the interventricular septum of HCM patients with cells ob-
tained from samples of non-failing/ non-hypertrophic surgical patients 
[47,48], observing several abnormalities in the homeostasis of intra-
cellular Na+ and Ca2+ in HCM myocardium [49] (Fig. 1). In particular, 
patch-clamp experiments showed a significant prolongation of the ac-
tion potential duration (APD) in HCM cardiomyocytes as compared to 
controls: APD at 90 % of repolarization was 916 ± 89 ms in HCM cells 
and 507 ± 61 ms in controls at 0.2 Hz pacing rate, 501 ± 27 ms in HCM 
vs. 361 ± 42 ms in control myocytes at 1 Hz. The prolonged APD pro-
moted an increased frequency of spontaneous depolarization events (i.e. 
early and delayed afterdepolarizations – EADs and DADs -), which 
correlated with the history of non-sustained VT in patients [47]. APD 
prolongation recorded in pathological cardiomyocytes resulted from a 
combination of multiple ion current alterations, including the significant 
reduction of the inward-rectifier K+ current (Kir2.1/IK1), of the transient 
outward K+ current (Kv4.3/Ito) and of the delayed rectifier K+ currents 
(IKs, IKr) recorded in HCM cardiomyocytes, as compared with control 
cells. Conversely, depolarizing currents such as L-Type Ca2+ current 
(ICaL) and late Na+ current (INaL) were both significantly increased in 
Table 1 
Experimental drug therapies for HCM.  
Drug Class Molecule Mechanism of action Experimental models tested on Clinical trial(s) OUTCOME of clinical trials 
Metabolic 
modulator 
Perhexiline Shift metabolism 
from free fatty acids 
to more efficient 
carbohydrate use 
MYBPC3 mutant mice [109] Randomized, placebo-controlled, in 
46 HCM patients [74] 
Improvement of functional capacity 
and diastolic filling [74] 
Ion channel 
blocker 
Ranolazine Late Sodium current 
(INaL) inhibition 
R92Q-TnT mice [82], 
hIPSC-CMs [145], human HCM 
ventricular tissue/cells [47] 
RESTYLE-HCM [77], randomized, vs. 
placebo, in >80 HCM patients 
No improvement of functional 




GS967 INaL inhibition Human HCM ventricular 
tissue/cells [48] 
LIBERTY-HCM (NCT02291237), in 
170 HCM pts. 
No improvement of functional 
capacity 
Class I anti- 
arrhythmic 
drugs 
Disopyramide Peak INa inhibition, 
INaL inhibition 
Human HCM ventricular 
tissue/cells [49] 
Several studies in pts. with obstructive 
HCM, including [76] 
Reduced LV outflow gradient, less 





Diltiazem L-type Ca2+ channel 
inhibition 
R403Q-MHC mouse model 
[106], hIPSC-CMs [169,190]. 
Pilot study in preclinical mutation 
carriers [107] 
Delayed the progression of diastolic 








L-type Ca2+ channel 
inhibition 






TPM1-HCM mouse model 
[108], MYH7-HCM rabbit 
model [128] 
Pilot study on 42 patients [130] Minimal changes of the indices of 
cardiac hypertrophy or fibrosis [130] 
Immuno- 
modulator 
Rapamycin Induction of 
autophagy 







of cardiac Myosin 
ATP-ase 
MYH7-HCM mouse model 
[110], R403Q porcine model 
[150], feline with HCM [155], 
hIPSC-CMs (MYBPC3 mut.) 
[198], hIPSC-CMs (MYH7 
mut.) [199] 
A completed open label phase 2 trial 
[156], a multicenter phase 3 trial on 
obstructive patients 
(EXPLORER-HCM) [157] and a pilot 
trial on non-obstructive patients [158] 
Reduction of LV outflow gradients and 
obstructive symptoms [156], limited 
reduction of ejection fraction. 
EXPLORER-HCM confirmed these 
positive results. In non-obstructive 
pts, it reduced plasma pro-BNP and 
TnI [158]. 
Statins Atorvastatin Reduction of LV 
fibrosis 
Rabbit HCM model [129] A pilot study on 32 HCM patients 
[131] 
No changes of the indices of fibrosis or 








No studies in HCM patients. No clinical studies  
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HCM cardiomyocytes, compared to control cells [47,49]. ICaL density in 
HCM cardiomyocytes was 7,02091 ± 27 pA/pF, while it was 5,54657 ±
0,42031 pA/pF in control cardiomyocytes (p < 0.05); INaL integral was 
195,65 ± 35,21 A*ms*F− 1 in HCM cardiomyocytes, vs. 74 ± 27 
A*ms*F− 1 in control cells (p < 0.01) [47]. We noticed that the 
myocardial levels of mRNA coding for K+ channel subunits were all 
significantly reduced, suggesting that K+ channels were down-regulated 
at gene expression level [47]. This modulation exerted at the tran-
scriptional level [50] is likely to be influenced, at least in part, by the 
enhanced activity of Ca2+/calmodulin-dependent protein-kinase II 
(CaMKII) in ventricles of HCM patients, via altered histone-deacetylase 
(HDAC) activation and function [47,51]. Besides the transcriptional 
effect mediating the down-regulation of K+ channel expression, the 
sustained activation of CaMKII plays a widespread role in driving the 
mechanisms of disease in the HCM myocardium, since it has been 
observed to promote cardiomyocyte remodeling and dysfunction by 
direct impairment of intracellular Ca2+ homeostasis. Specifically, we 
and others hypothesized that a sustained increase of [Ca2+]i is directly 
caused by sarcomeric mutations (through the increased myofilament 
Ca2+ sensitivity or the impaired energetics and the associated dysfunc-
tion of SERCA), causing an initial hyper-activation of CaMKII. Once 
activated, CaMKII is characterized by a transition to an active 
auto-phosphorylated state, increasing the activity of CaMKII itself [52] 
and consequently potentiating the phosphorylation of all the down-
stream targets (ryanodine receptors, Ca2+ channels, Na+ channels, 
phospholamban) [53–55]. The increased activity of CaMKII has been 
identified in animal models and human samples with cardiac hyper-
trophy and/or diastolic dysfunction [53,54,56]. In fact, we noticed that 
the auto-phosphorylation of CaMKII was 3.5-fold higher in human HCM 
samples from patients undergoing surgical myectomy, as compared with 
controls [47]. L-type Ca2+ current is also markedly affected by the 
activation of CaMKII: in fact, we also observed that in HCM car-
diomyocytes the inactivation phase of ICaL was slower, through 
increased phosphorylation of the L-type Ca2+ channel β-subunit, [47,48, 
57]; this led to increased and prolonged systolic Ca2+ entry and 
contributed to the accumulation of [Ca2+]I during the diastolic phase. 
The increased ICaL density recorded in HCM cells [47] is also caused by 
the slightly increased levels of CaV1.2 protein, which may contribute to 
the genesis of EADs. Another deeply altered ion current in human HCM 
cardiomyocytes is late sodium current (INaL), which was found consis-
tently increased in human HCM cardiomyocytes we obtained from sur-
gical samples. The increased INaL directly contributes to APD 
prolongation [47], in line with other human and animal models of hy-
pertrophy [58,59]. In HCM myocardium, CaMKII plays a fundamental 
role in the increase of INaL [60,61]. In fact, the increased phosphoryla-
tion levels of cardiac Na+ channel (NaV1.5) mediated by CaMKII [47] 
impair current inactivation. The role of the aforementioned ion current 
changes in the prolongation of APD observed in human HCM car-
diomyocytes was also validated by mathematical models [47,62,63]. 
CaMKII activity is also improved by pro-oxidant conditions [64]. 
Erickson et al. [65] showed that oxidation of paired methionine residues 
in the regulatory domain leads to stimulation of CaMKII function in the 
absence of Ca2+/CaM, supporting an independent role of pro-oxidant 
environment, such as un-scavenged H2O2. Among the causal factors, 
angiotensin II (AngII) may activate CaMKII via NADPH oxidase. Un-
published data obtained from our recent studies confirmed the presence 
of a high level of oxidation of CAMKII in myectomies from HCM 
patients. 
Besides studying the phenotype of single cardiomyocytes, we also 
employed human ventricular samples from obstructive HCM patients 
undergoing myectomy to dissect single intact trabeculae, which were 
used for recordings of isometric force under controlled mechanical 
conditions and specific pacing protocols [47–49]. In summary, we 
identified a slower kinetics of twitch relaxation and a higher diastolic 
tension at high pacing rates in HCM vs. control trabeculae. At variance 
with trabeculae from failing hearts, positive inotropic responses to 
increased pacing frequency and β-adrenergic stimulation were pre-
served in HCM trabeculae [47,48]. Intact trabeculae, such as single 
viable cardiomyocytes, need to be obtained from fresh samples and can 
therefore be studied only for a relatively short time after the sample is 
obtained from the operating room. However, ventricular tissue from 
HCM patients can be snap frozen in liquid nitrogen and used at a later 
time to perform mechanical studied in skinned (demembranated) 
preparations (i.e. myocardial preparations where all membranes are 
dissolved using detergents). These include (i) skinned trabeculae/large 
tissue strips [34,47,66,67] (used to assess myofilament ATPase rate 
using enzymatic assays), (ii) skinned single cells/bundles [68,69] (used 
to assess myofilament length-dependent activation and calcium sensi-
tivity of force generation) and (iii) single myofibrils [34,35,67,70] (used 
to study cross-bridge attachment and detachment kinetics). Studies on 
human skinned preparation from HCM patients, conducted in the labs of 
Prof. van der Velden and Prof. Poggesi with the aforementioned tech-
niques, led to important insights on the pathogenesis of myofilament 
dysfunction in HCM. In particular, they found that most MYH7 and 
MYBPC3 mutations, as well as some TNNT2 mutations, are associated 
with a faster cross-bridge cycling rate, that in turn determines a lower 
maximal force and an increased ATP consumption per unit of force 
produced (i.e. increased energy cost of contraction). Indeed, HCM is 
known to be characterized by metabolic impairment caused by an 
increased energetic cost of myocyte contraction [35], that could 
significantly contribute to the pathophysiology of the disease [71]. 
Moreover, the consideration that the levels of high-energy phosphates in 
the myocardium are significantly affected even in asymptomatic HCM 
[72] and in the pre-hypertrophic stage of the disease [71] strengthens 
the concept that the energy deficiency in HCM plays a leading role in the 
onset and progression of cardiac remodeling. Considering high energy 
requirements of the heart, cardiac energy deficiency is supposed to 
represent a contributory cause of the early diastolic relaxation slowing 
(energy dependent phenomenon correlated with exercise limitation) 
typical of HCM [73]. The role of energy deficiency as a determinant of 
HCM-related patho-mechanisms [35] was further investigated by 
Abozguia and coworkers, who tested perhexiline in an attempt to shift 
metabolism from free fatty acids to a more efficient use of carbohydrates 
[74] (Table 1). In particular, the authors of this study evaluated the 
potential effects of perhexiline on exercise performance in a cohort of 46 
patients with symptomatic exercise limitation (peak V̇O2 <75 % of 
predicted) caused by nonobstructive HCM. Patients enrolled in this 
study were randomized to perhexiline 100 mg (n = 24) or placebo (n =
22). The rationale of the clinical trial was based on the ability of per-
hexiline to increase exercise capacity through enhancement of cardiac 
energetics and improvement of LV relaxation in HCM patients. 
Myocardial ratio of phosphocreatine to adenosine triphosphate, an 
established marker of cardiac energetic status (measured by 31P mag-
netic resonance spectroscopy), left ventricular diastolic filling (heart 
rate normalized time to peak filling) at rest and during exercise 
(measured through radionuclide ventriculography) and peak V̇o2 were 
assessed at baseline and at the end of the study (4.6 ± 1.8 months). 
Perhexiline confirmed the leading hypothesis according to which altered 
myocardial energetics drives the major pathophysiological changes 
occurring in HCM myocardium. Indeed, perhexiline augmented 
myocardial ratios of phosphocreatine to adenosine triphosphate (from 
1.27 ± 0.02 to 1.73 ± 0.02 versus 1.29 ± 0.01 to 1.23 ± 0.01 in 
placebo-treated patients; P = 0.003), normalized time to peak filling 
(nTTPF) between rest and exercise (0.11±0.008 to 0.01±0.005 s. versus 
0.15±0.007 to 0.11±0.008 s. in placebo-treated patients; P = 0.03) and 
improved the functional capacity of HCM patients (tested with cardio-
pulmonary stress test). Therefore, the present study suggests that per-
hexiline positively impacts on the quality of life of HCM patients by 
significantly impairing the metabolism of free fatty acids and serum 
glucose [74]. 
Living cardiomyocytes isolated from human cardiac surgical speci-
mens also represent an effective tool to test novel pharmacological 
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molecules, thus evaluating their potential therapeutic effects (Table 1). 
Considering the multiple ion current alterations observed in HCM (the 
increased INaL is one of the most important contributors to the electro-
physiological and Ca2+i alterations occurring in ventricular myocytes) 
[47,49] and their resulting effects in the pathomechanisms of the dis-
ease, an adequate therapeutic approach could be played by the use of 
molecules able to affect ion channel kinetics. As consequence, we tested 
whether INaL blockade with ranolazine (10 μmol/L) could represent an 
effective option to reduce the electromechanical dysfunction in HCM 
myocardium. At 10 μmol/L, ranolazine reduced INaL integral from 195, 
65 ± 35,21 A*ms*F− 1 to 77,29 ± 18,21 A*ms*F− 1 in HCM myocytes (p 
< 0.01) [47]. We observed that ranolazine, through decrease of intra-
cellular Na+ overload, restored Ca2+ extrusion through the forward 
mode of Na–Ca exchanger (NCX) and reduces Ca2+ influx via NCX 
reverse-mode, thus determining an acceleration of Ca2+ transient ki-
netics and mediating a reduction of diastolic [Ca]2+i. In particular, INaL 
block by ranolazine significantly reduced APD in HCM cardiomyocytes: 
APD at 0.2 Hz was 946 ± 95 ms at baseline and 707 ± 71 ms in the 
presence of ranolazine (p < 0.01); at 1 Hz, APD was reduced from 557 ±
44 ms to 443 ± 32 ms (p < 0.01). In addition, ranolazine halved the rate 
of EADs, highlighting the antiarrhythmic potential of ranolazine in this 
disease. Moreover, via normalization of intracellular Ca handling and 
diastolic Ca, ranolazine may improve diastolic function in HCM patients 
[47]. Additionally, DADs were reduced by 60 % in the presence of 
ranolazine. To confirm that these beneficial effects exerted by ranolazine 
on HCM cardiomyocytes [47] were directly mediated by INaL inhibition 
(and not by potential pleiotropic effects of the drug, such as the stabi-
lization of ryanodine receptors [49]), we tested the selective INaL-inhi-
bitor, GS-967, in isolated human HCM cardiomyocytes [48]. In HCM 
myocardium GS-967 exerted effects that were qualitatively and quan-
titatively similar to the effects of ranolazine in the same cells (i.e. INaL 
reduction, accelerated AP kinetics, diminished rate of arrhythmogenic 
EADs, decreased diastolic [Ca2+], suppression of DADs, acceleration of 
Ca2+-transient kinetics). However, these effects were observed at a 20 
times lower concentration (10 μM ranolazine vs. 0.5 μM GS-967), sug-
gesting that GS-967 has an increased selectivity for INaL and a higher 
potency of inhibition. We observed that disopyramide, a Class I anti-
arrhythmics drug, was also capable of blocking INaL in HCM car-
diomyocytes [49]. Disopyramide is commonly used in obstructive HCM 
due to its negative inotropism [75,76]. This effect results from the sum 
of different molecular actions exerted at cellular level. Indeed, dis-
opyramide is able to slightly reduce ICa-L, an effect that is, at least in part, 
responsible for the decrease of systolic intracellular [Ca2+] in the car-
diomyocyte. However, we observed that the concurrent inhibition of 
peak and late INa by disopyramide is also necessary for its negative 
inotropic action [49]. Finally, disopyramide interacts with ryanodine 
receptors, stabilizing them and reducing their probability to open, thus 
decreasing the amount of systolic Ca2+ release. Disopyramide was also 
observed to exert an anti-arrhythmic effect in HCM cardiomyocytes: INaL 
and ICa-L inhibition by disopyramide mediates the reduction of AP 
duration, ultimately shortening AP plateau duration and thus mediating 
a reduction of arrhythmogenic triggers in HCM cardiomyocytes. Indeed, 
disopyramide reduced EADs, a direct consequence of AP shortening, and 
abolished DADs, thanks to the reduced diastolic [Ca2+] and SR Ca2+
content, as well as to the stabilization of the closed state of the RyR [49] 
(Fig. 1). 
In parallel with studies on intact cardiomyocytes, we also tested 
ranolazine, GS-967 and disopyramide in intact and skinned trabeculae, 
evaluating their effects on mechanical myocardial performance in 
human HCM myocardium [47–49]. In brief, we observed that ranolazine 
and GS-967 slightly accelerated twitch relaxation and lowered diastolic 
tension at higher pacing frequencies, while twitch amplitude was un-
changed. Disopyramide had a concentration-dependent negative 
inotropic effect, that was paralleled by an acceleration of relaxation. 
Despite the promising results obtained in human cardiomyocytes, a 
multicenter, placebo-controlled study with ranolazine in non- 
obstructive HCM patients with exercise-limiting symptoms revealed 
that ranolazine had minimal beneficial effects on exercise capacity [77]; 
nonetheless, ranolazine reduced circulating pro-BNP and markedly 
decreased arrhythmogenic ventricular ectopies in patients [77]. Elec-
lazine, the equivalent of GS-967 developed for use in patients, was tested 
on over 170 HCM patients in the multicenter study LIBERTY-HCM 
(NCT02291237); again, no significant beneficial effects on exercise ca-
pacity were noted in treated patients (https://clinicaltrials.gov/ct2/sho 
w/study/NCT02291237). 
Skinned human myocardial preparations from HCM patients can be 
used to assess the effects of drugs that directly target myofilaments. 
Although no studies have been published so far testing drugs in human 
HCM demembranated trabeculae, cells or single myofibrils, several 
studies are ongoing testing the effects of the selective myosin inhibitor 
mavacamten (see below) in human HCM samples from patients carrying 
different mutations. 
2.2. Animal models as an invaluable research tool to model 
cardiomyopathies 
2.2.1. Rodent models 
Despite their high translational value, studies on myocardial samples 
from patients with HCM show several restrictions, being limited by the 
scarce availability of surgical material and the wide heterogeneity 
among patients (the intrinsic genetic background variations, the various 
clinical expression and environmental influences) [78]. Moreover, sur-
gical human tissue models are representative of a relatively advanced 
disease stage of HCM, therefore is often impossible discerning primary 
players, induced by a particular gene variant, from the secondary and 
tertiary mechanisms resulting from myocardial adverse remodeling. 
In the past 20 years, animal models of HCM have been developed as 
an inestimable research platform for studying HCM pathophysiology, 
disease progression and for testing new therapies. Animal models can 
represent an effective solution to the limitations of using surgical human 
samples, with inbred strains eliminating variabilities in the genetic 
background. Such models were vital to get insight into the causative role 
of gene variants in HCM and downstream pathogenic signaling path-
ways. Additionally, they have provided novel knowledge into potential 
new interventions for the therapeutic management of the disease. Most 
of these animal models were initially created in mice, as rodent models 
are characterized by several advantages that facilitate their use in sci-
entific research (Fig. 2). 
The first animal model developed to study the pathogenesis of HCM 
was a mouse line carrying a missense mutation at codon 403 in the 
α-MyHC gene, corresponding to the human β-MyHC R403Q mutation 
[79]. The R403Q model showed different pathological features such as 
myocellular disarray, fibrosis, and diastolic dysfunction, faithfully 
replicating the pathology observed in human tissues [79]. Moreover, the 
rate of arrhythmogenic events was considerably increased in this mouse 
model, as compared with wild type (WT) mice [80]. However, left 
ventricular (LV) hypertrophy (the hallmark of HCM) was not present in 
this mouse model. A report from Tyska and coworkers revealed that the 
R403Q substitution is able to enhance both the ATP-hydrolytic and the 
mechanical performance of the mutant cardiac myosin, increasing 
actin-activated ATPase activity and the average force generation. Ex-
periments were performed on whole cardiac myosin purified from a 
mouse model of familial hypertrophic cardiomyopathy (FHC), carrying 
the R403Q mutation, to eliminate potential uncertainties associated 
with protein expression systems. The observed increase of myosin 
ATPase activity suggest that this mutation may affect the mechanical 
synchronization between the 2 “heads” of a cardiac myosin molecule, 
impairing the energy transduction process through a “gain of function” 
mechanism [81]. A rodent model carrying a similar mutation (deletion 
of amino acids 468–527 in the actin-binding domain of α-MyHC) also 
reproduced the landmark histologic features of HCM and showed 
marked hypertrophy of the left- and right-ventricular walls at 4 months 
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of age, thus representing an efficient model to study the 
patho-mechanisms of HCM [82]. Another transgenic mouse line 
expressing a mutated α-MyHC (missing the light chain binding domain) 
[83] showed the typical histologic features of HCM. Hearts obtained 
from these mice are characterized by asymmetric hypertrophy, partic-
ularly involving the anterior LV wall. 
Myosin binding protein-C (MyBP-C) is the most common gene 
involved in human HCM pathogenesis. Mouse lines carrying a modified 
MyBP-C with a deletion of the entire myosin and titin-binding domains 
were developed and studied [84]: these transgenic mice showed light 
hypertrophy, sarcomere disarray, and altered exercise capacity [85]. 
Moreover, to study the pathogenic potential of the cMyBP-C-DC10 
mutation (the most common mutation associated with the develop-
ment of HCM), transgenic mice expressing cardiac specific 
cMyBP-C-DC10mut were generated. Transgenic expression of 
cMyBP-C-DC10mut is responsible for all the hallmarks of HCM in mice. 
In this transgenic line the mutated protein lead to an improper assembly 
of the cardiac sarcomere through a poison-peptide effect. Mice showed a 
typical HCM phenotype with activation of pro-hypertrophic signaling in 
the myocardium, determining LV hypertrophy, diastolic dysfunction 
and contractile abnormalities; moreover, cardiac remodeling was asso-
ciated with LV fibrosis [86]. Studies conducted in a knock-in mouse 
model harboring a clinically-relevant point mutation of MYBPC3 (G > A 
transition in the last nucleotide of exon 6) led to the concept that dia-
stolic dysfunction and myofilament Ca2+ sensitization (two main path-
ogenic marks of HCM) are initial phenotypic consequences of cMyBP-C 
mutations, preceding the development of left ventricular hypertrophy 
(LVH) in HCM. As mentioned above, mutations in Troponin T (TNNT2), 
cardiac Troponin I (TNNI3) and α tropomyosin (TPMI) account for about 
5 % of HCM cases each [87–92]. In the latest years, transgenic rodent 
models carrying mutations in the α-tropomyosin gene were generated 
and studied. Among these, a rodent model harboring the D175N α-TM 
mutation was able to replicate some histo-pathologic features of human 
HCM, such as myocellular disarray and hypertrophy, with altered 
contractility and relaxation in vivo. Although the isovolumic phase of 
systole was normal in these mutant mice, abnormalities were evident 
with the onset of contraction, consistent with the abnormal fractional 
shortening observed in echocardiographic studies. While the systolic 
performance was slightly reduced, the authors described a 40 % 
reduction of negative dP/dTmax during LV relaxation in mutant mice 
compared to controls. Moreover, the D175N tropomyosin mutation was 
observed to cause increased myofilament calcium sensitivity in this 
mouse model [93]. Different mutations in cardiac troponin T (cTnT) can 
cause familial HCM. To gain deeper insights into patho-mechanisms of 
“thin-filament” HCM and to evaluate the main features of the associated 
phenotypes, Tardiff and coworkers developed transgenic mouse lines 
expressing 30 %, 67 %, and 92 % of their total cTnT as a missense 
(R92Q) allele analogous to one found in human HCM. We performed an 
electrophysiological and morpho-functional analysis of single car-
diomyocytes isolated from R92Q hearts to evaluate whether this model 
could finely reproduce HCM in humans. R92Q hearts showed different 
common markers of HCM, such as interstitial fibrosis, mitochondrial 
structural alterations, diastolic dysfunction and hypercontractility [94]. 
Moreover, cardiac myocytes isolated from R92Q mice were character-
ized by increased diastolic calcium resulting in an impaired Ca2+
handling and slower Ca2+ transient kinetics combined with an increased 
rate of spontaneous arrhythmogenic electrical events [95], replicating 
data we obtained performing Ca2+-fluorescence experiments on single 
cardiomyocytes isolated from human HCM samples [41]. Besides 
various limitations associated to the use of rodent tools to model HCM 
(summarized at the beginning of 2.2.2 paragraph) and except for AP 
duration that is shorter in R92Q compared to control cardiomyocytes (in 
human HCM cardiomyocytes AP kinetics are slower compared to control 
cells), R92Q cardiomyocytes can accurately reproduce the different 
pathogenic features proper of human HCM, suggesting that among 
murine models of HCM, R92Q transgenic mouse could play a leading 
role to gain deeper insights into cellular patho-mechanisms of HCM. 
Sarcomeric mutations in troponin T (TnT) or TnI are associated with 
a high risk of SCD, even if cardiac hypertrophy is not evident [96,97]. 
Baudenbacher and coworkers hypothesized that the increased 
Fig. 2. Transgenic animals to model HCM and for pharmacological testing. This table summarizes all animal models (transgenic and spontaneous models) described 
in the text to gain deeper insights to pathomechanisms of HCM and to screen novel drugs. 
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arrhythmia susceptibility could be independently and directly caused by 
the raised myofilament Ca2+ sensitivity, a direct consequence of the 
mutations of the sarcomere regulatory proteins. They confirmed this 
hypothesis by developing transgenic mice carrying HCM-linked TnT 
mutations conferring strong Ca2+ sensitization (TnT-I79N, associated 
with a high risk of SCD at young age [96,98]), intermediate increase of 
Ca2+ sensitivity (TnTF110I), or minimal changes (TnT-R278C, associ-
ated to a better prognosis in patients [99–101]). Myofilament Ca2+
sensitization was effectively observed to be a novel and independent 
mechanism of arrhythmogenesis despite the absence of histological 
abnormalities (fibrosis, myocardial disarray), commonly considered as 
the main cause of arrhythmias in HCM. Arrhythmogenesis arose from 
increased dispersion of ventricular activation at fast heart rates, conse-
quently resulting in reentry arrhythmias [98]. 
The role of increased myofilament Ca2+ sensitivity in HCM patho-
genesis was evaluated also in other animal models, such as guinea pigs. 
Murine cardiomyocytes differ from both human and guinea pig for what 
concerns structure and function. In particular, human and guinea pig are 
characterized by slow MyHC (β isoform) while murine cardiomyocytes 
contain predominantly fast MyHC (α isoform) [102]. There are also 
marked electrophysiological differences: cardiac AP in mice differ 
consistently in waveform, lacking any appreciable plateau [103]. Rob-
inson and co-workers developed a stable but short-term transgenic 
cardiomyocyte guinea pig model of HCM through adenoviral expression 
of HCM-associated variants in the genes encoding for human troponin-T, 
troponin-I, and alpha-tropomyosin (R92Q, R145G, and D175N respec-
tively), in adult left ventricular cardiomyocytes from the guinea-pig 
heart. Isolated cells showed different pathogenic alterations that are 
typical of human HCM, such as abnormal Ca2+ transients, increased 
cytoplasmic [Ca2+] and a clear activation of Ca2+-dependent signaling 
mediated by CaMKII. Moreover, increased myofilament Ca2+ affinity, 
one of the primary consequences of HCM sarcomeric mutations in 
humans, was observed to double the total Ca2+ buffering by the myo-
filaments, directly altering intracellular Ca2+ homeostasis. This car-
diomyocyte model also showed and confirmed a direct correlation 
between myofilament Ca2+ buffering, impaired Ca2+ handling and the 
inception of Ca2+-mediated hypertrophic signaling [104]. Human HCM 
can be modelled also in rats. A transgenic rat model of HCM, expressing a 
truncated human TnT protein missing exon 16, was characterized by a 
degree of diastolic dysfunction similar to that observed in the mouse 
model, as well as increased predisposition to ventricular arrhythmias 
[105]. 
Besides their usefulness in assessing the patho-mechanisms and 
electro-mechanical abnormalities characterizing human HCM, trans-
genic murine models represent a fundamental basis to test novel mole-
cules with possible pharmacological action, before proceeding with 
larger animal models and, eventually, with clinical trials in patients 
(Table 1). The R403Q-MHC model, the first animal model developed to 
study the pathogenesis of HCM [79] was used to test the L-type Ca2+
channel inhibitor diltiazem, which showed to prevent the development 
of HCM-related pathological changes in transgenic mouse hearts. In 
particular, decreased levels of RyR2 and SR Ca2+ binding proteins such 
as calsequestrin were observed in αMHC403/+ myocytes and were 
restored to normal levels as a direct consequence of the inhibition of 
L-type Ca2+ channels by diltiazem. As a consequence of the reduced 
intracellular Ca-overload, the early administration of diltiazem to 
αMHC403/+mice reduced cardiac hypertrophy and fibrosis, thus pre-
venting the cardiac histopathology and hemodynamic consequences of 
this sarcomere protein mutation [106]. In line with that, preventive 
treatment with diltiazem of HCM mutation carrier individuals (identi-
fied in family screening programs), prior to the development of HCM 
cardiac phenotype, delayed the progression of diastolic dysfunction an 
ventricular thickening [107]. As mentioned above, INaL is deeply 
involved in HCM pathogenesis. R92Q-TnT transgenic mice accurately 
reproduce all different pathophysiological features of HCM, including 
the increased INaL. Acute treatment with ranolazine lowered both 
intracellular [Na+] and diastolic [Ca2+] in R92Q-TnT cardiomyocytes 
through the inhibition INaL [95]. We established to chronically treat 
R92Q transgenic mice with oral ranolazine since birth, to evaluate 
whether ranolazine treatment effectively blocked the development of 
diastolic dysfunction in HCM transgenic mice [95]. Our results showed 
that life-long ranolazine treatment exerted a preventive effect on the 
development of HCM patho-mechanisms in the hearts of R92Q-TnT 
murine models, counteracting the onset of LV hypertrophy, tissue 
fibrosis and diastolic dysfunction. In particular, the prevention of 
pathological excitation-contraction-coupling abnormalities is respon-
sible of the preserved diastolic function in treated R92Q-TnT mice. In 
fact, in cardiomyocytes isolated from ranolazine-treated mice, the 
physiological diastolic Ca2+ level is preserved and Ca2+ transient ki-
netics is faster because of the maintained SERCA and NCX function [95]. 
The increased production of ROS demonstrated in the hearts of pa-
tients with HCM may mediate HCM-related electro-mechanical abnor-
malities in combination with intracellular Ca2+ overload [47]. 
Therefore, the use of anti-oxidant compounds could represent a helpful 
strategy in the therapeutic management of HCM. Moreover, considering 
that ROS are key determinants of the progression of cardiac hypertro-
phy, the oxygen radical scavenger compound N-acetyl-cysteine (NAC) 
could act a leading role in the reduction of the pathological burden in the 
ventricles of animal models and patients with HCM. NAC was tested on a 
mouse TPM1-HCM model and it effectively reduced diastolic dysfunc-
tion and hypertrophy [108]. Echocardiography was used to evaluate 
heart morphology and diastolic function. While treatment with NAC 
exerted a partial amelioration on left atrium (LA) size, it significantly 
reduced left ventricle (LV) mass, returning it back to NTg levels. NAC 
treatment was also capable to correct diastolic dysfunction and reduce 
E/A ratios to NTg levels [108]. 
As stated above, the main role played by the metabolic impairment in 
the pathophysiology of HCM [71] and the resulting increased energetic 
cost of myocyte contraction [35] suggest that reverting energy depletion 
could represent a major improvement in the therapeutic approach of 
HCM. The ability of the metabolic modulator perhexiline to shift 
metabolism from free fatty acids to glucose utilization in HCM patients 
[63] was also tested by Gehmlich and coworkers in Mybpc3-targeted 
knock-in mouse model of HCM [109]. Performing non-targeted metab-
olomic analysis (applying ultra-high performance liquid 
chromatography-mass spectrometry), Gehmlich and colleagues 
observed that perhexiline administration induced a phenotypic modifi-
cation of the cardiac metabolome with 272 unique metabolites, 
impairing fatty acids and improving glucose utilisation, thus suggesting 
an evidence of altered fatty acid transport into mitochondria and 
increased glucose utilisation. These data suggest that perhexiline treat-
ment significantly modify cardiac metabolome increasing ATP pro-
duction and myocardial efficiency, thus ameliorating HCM phenotype in 
Mybpc3-targeted knock-transgenic model [109]. 
Intrinsic myofilament hyper-activation and abnormal myofilament 
energetics are believed to represent the primary change determined by 
sarcomeric HCM. As a consequence, correcting the primary energetic 
abnormalities in mutant myofilaments may prevent the formation of LV 
hypertrophy and of the arrhythmogenic tissue substrate. Myosin heads 
rapidity of movement along actin filaments and their ability of force 
generation directly influence sarcomere power output. Considering that 
increase of the total cycle time of myosin ATPase reduces the temporal 
interaction between cardiac myosin and actin, resulting in fewer myosin 
molecules in an active state to generate force, accordingly decreasing 
ensemble force generation, Green and coworkers screened different 
molecules for their capability to reduce the maximal actin-activated 
ATPase rate of myosin, and tested them in bovine myofibrils [110]. 
Among the chemical compounds identified through this screen, they 
focused on MYK-461, evaluating in-depth its potency and the pharma-
ceutical properties. Treatment of mouse cardiac myofibrils with the 
myosin inhibitor mavacamten (MYK-461) reduced ATPase activity in a 
dose-dependent manner; in particular, maximal doses of MYK-461 (>10 
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μM) reduced the maximal ATPase rate by ~90 %. Individual steps of the 
myosin chemomechanical cycle through that MYK-461 inhibits myosin 
ATPase were then analyzed in detail by Green and coworkers perform-
ing transient kinetic experiments: the rate of phosphate release and the 
rate-limiting step in the chemomechanical cycle were observed to be 
reduced in a dose-dependent manner by the administration of MYK-461, 
that exerted its effects without slowing adenosine diphosphate (ADP) 
release. The aforementioned data show that MYK-461 decreases the 
ratio of strongly bound state time to total cycle time of myosin, conse-
quently reducing the ensemble force, power, and contractility produced 
by the sarcomere [110]. With this mechanism, mavacamten restored the 
correct myofilament energetic properties in a mouse MYH7-HCM model 
and prevented the development of both LV hypertrophy and fibrosis 
[110]. 
However, no significant effects on disease onset and progression 
were noticed when the drug was administered to a mouse MYBPC3-HCM 
model [111], suggesting that myosin inhibition could be a relevant 
therapeutic option for specific HCM genotypes. 
2.2.2. Rabbit models 
Notwithstanding their avail in the investigation of the molecular 
basis of HCM, rodent models show different limitations and therefore 
show constrained predictive significance in translating relative patho-
physiological information to humans. These limitations, mainly driven 
by species differences (e.g., anatomy, physiology, metabolism, lifespan, 
and response to treatment), could promote translational failures when 
drugs that showed promising results in rodents are later tested in human 
clinical trials [112]. Significant differences between the mouse and 
human are physiologically evident in the regulation of Ca2+ homeostasis 
during contraction and relaxation and when disease-specific patholog-
ical alterations of Ca2+ fluxes occur [113,114]. Moreover, rodent models 
show limitations for their use in evaluating the increased ventricular 
arrhythmogenesis, one of the hallmarks of HCM. In fact, the beating 
typical of the mouse heart is almost ten times faster than the human 
heart and this faster rate influences the refractory period, which directly 
correlates with the incidence of arrhythmias [115]. The aforementioned 
limitations underscore the importance of working on relevant preclini-
cal models that represent an intermediate step between transgenic ro-
dent models and human clinical medicine [112]. Rabbits are unlikely to 
represent the primary transgenic model to study HCM because of the 
difficult process and wide expenses needed for developing these trans-
genic lines, as well as the lack of validated advanced genetics ap-
proaches in this species [116]. However, they show a number of 
advantages over the mouse, for studying cardiovascular disease [117] 
(Fig. 2). In fact, rabbits more accurately reflect the human system and 
are larger in size, which facilitates investigations such as echocardiog-
raphy or invasive electrophysiology. Other advantages of transgenic 
rabbit models are related with the expression of β-MyHC: in the mouse 
the β-MyHC protein is expressed in the ventricles only at subsided levels 
[118], but represents the predominant protein in the ventricle of rabbits 
(the same as in humans), showing an approximately 98 % homology to 
human β-MyHC protein [119,120]. Moreover, skinned rabbit and 
human cardiomyocytes are characterized by similar contractile prop-
erties [121]. 
As mentioned above, the first animal model developed to gain deeper 
insights into the pathogenesis of HCM was the MyHC-R403Q transgenic 
line [28]. The demand for an animal model that more closely and 
faithfully recapitulated human HCM clinical/pathological phenotype 
was fulfilled by producing a transgenic rabbit harboring the R403Q 
mutation in human β-MyHC [117]. The phenotype of the R403Q 
transgenic rabbit virtually replicated that of humans, showing gross 
cardiac hypertrophy, myocyte and myofibrillar disarray, interstitial 
fibrosis, diastolic dysfunction associated with preserved systolic func-
tion. Moreover, these transgenic rabbits were characterized by a high 
occurrence of premature death. The aforementioned pathogenic features 
make the β-MyHC-R403Q transgenic rabbits a suitable proxy of human 
HCM for pathogenetic and therapeutic studies. To further evaluate the 
different patho-mechanisms of HCM and determine the temporal evo-
lution of cardiac HCM phenotypes, Sherif and coworkers deeply inves-
tigated the R403Q transgenic rabbit over a four years period using 
multiple techniques [122]. Ca2+ sensitivity of myofibrillar ATPase ac-
tivity decreased very early during the progression of cardiac pathology, 
suggesting that the impairment of myocardial energetics may represent 
a primary defect contributing to the pathogenesis of HCM [123]. Myo-
cyte disarray is another HCM feature that occurred early, independently 
from hypertrophy and fibrosis. Finally, β-MyHC-R403Q transgenic rab-
bits showed a progressive deterioration of ventricular diastolic function 
with aging, replicating the evolution of HCM in humans [1]. Collec-
tively, these pieces of evidence suggest that different independent 
mechanisms contribute to the pathogenesis of HCM [122]. Lowey and 
co-workers used a similar transgenic rabbit to evaluate the consequences 
of the R403Q mutation on actin–myosin interactions at the molecular 
level [124]. They observed myosin loss-of-function in mutated myofi-
brils from the rabbit, comparable to the findings from studies in trans-
genic mouse models with the same mutation [125,126]; indeed, R403Q 
myofibrils generated a reduced power when compared with control 
myofibrils. In particular, the maximum tension, as well as the kinetic 
rates for activation and myofibril relaxation, were all significantly 
reduced in the ventricular R403Q myofibrils with respect to controls. A 
transgenic rabbit carrying the cTnI-R146G mutation in cTnI gene was 
generated and studied [127]. The ventricles from the cTnI-R146G rab-
bits showed myofiber disarray, interstitial fibrosis and mild apical 
ventricular hypertrophy at 18–24 months of age. All in all, transgenic 
rabbit models represent a novel and informative source to investigate 
the HCM-related pathogenic mechanisms and develop innovative ther-
apies [127]. The increased production of reactive oxygen species 
observed in human HCM cardiomyocytes led the researchers to test 
antioxidant compounds on transgenic rabbit models of HCM. Thus, 
based on the rationale that reactive oxygen species are important 
determinant of disease progression in cardiac hypertrophy including 
HCM, NAC was used to treat a rabbit MYH7-HCM model [128]. Treat-
ment with NAC caused the reduction of established LVH and fibrosis in a 
rabbit MYH7-HCM model, showing the beneficial role of NAC on his-
topathological features of HCM. In particular, echocardiographic indices 
of cardiac hypertrophy were regressed to normal values after 12-month 
treatment with NAC. Myocyte cross-sectional area was increased by ≈20 
% in transgenic rabbits in the placebo group compared with the non-
transgenic group. In contrast, myocyte cross-sectional area in the NAC 
group was comparable to that in the nontransgenic rabbits [128]. Statins 
may also represent a helpful approach to reduce the fibrotic condition in 
hypertrophic ventricles, one of the main histopathological alterations of 
human HCM. Indeed, treatment with atorvastatin reduced cardiac hy-
pertrophy and fibrosis in a rabbit HCM transgenic model [129]. Despite 
these promising preclinical results, a pilot clinical trial with NAC in 42 
patients with HCM showed no significant effects on LV hypertrophy and 
fibrosis, as evaluated with cardiac magnetic resonance [130]. Moreover, 
a pilot study with atorvastatin in 32 HCM patients did not show any 
changes of the echocardiographic indices of cardiac hypertrophy and 
function in treated subjects [131]. 
2.2.3. Zebrafish 
The zebrafish (Danio rerio) is a novel research tool to gain deeper 
insights into the genetic basis of human cardiomyopathies. Indeed, 
zebrafish models have multiple interesting advantages: 1) availability of 
simple gene editing approaches, 2) easy to use for drug screening, 3) low 
cost of breeding and maintenance, and 4) accessibility of both embry-
onic models and adult animals. Moreover, the cardiac anatomy of 
zebrafish, with a single ventricle and a single atrium, makes zebrafish 
one of the simplest vertebrates for the study of human cardiomyopathies 
[132]. 
Zebrafish genome sequencing was finally completed in 2013, 
showing that 82 % of the known human pathology-related genes have an 
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orthologous gene in the genome of the zebrafish. This simple animal 
model can be combined with the application of TALEN or the CRISPR/ 
Cas9 genome-editing toolsets. Such techniques can be used for the 
introduction of specific DNA elements, such as the specific genetic 
variants observed in patients with cardiomyopathies, by homologous 
recombination, thus creating disease models carrying patient-specific 
mutations. Moreover, the translucency of zebrafish embryos represents 
a useful feature, allowing exploitation of high-performance high-reso-
lution in vivo observations of the heart. Such advanced imaging ap-
proaches helped investigating the mechanisms and timing of 
cardiomyocyte differentiation and maturation during cardiac develop-
ment [133]. 
MacRae and colleagues developed a zebrafish model of a pathogenic 
variant of human cardiac TNNT2 [134]. Besides increasing the knowl-
edge on the early developmental consequences of HCM-related muta-
tions, this transgenic research tool led to a deeper comprehension of the 
genetic and environmental features prompting the onset and progres-
sion of pathological myocardial remodelling in HCM. Moreover, they 
demonstrated that this TNNT2 mutation perturbed the physiological 
Ca2+ handling of the cardiac cell. McRae and coworkers performed 
high-resolution Ca2+ imaging in order to determine the effects of sar-
comeric TNNT2 mutation on cardiomyocyte Ca2+ handling during early 
heart development of Zebrafish embryos. The most evident difference 
between pathologic and control embryos was the shortening of the Ca2+
transient duration (CTD50) in the TNNT2 mutant hearts. This shortening 
was observed in both atrium and ventricle but was particularly evident 
in the outer ventricular curvature and in the mid ventricle [134]. These 
results supported the idea that that the arrhythmic risk observed in HCM 
patients is not a simple and direct consequence of cellular disarray, but 
involves specific alterations of cardiomyocyte electrophysiology and 
Ca-homeostasis. This embryonic zebrafish model carrying a 
patient-specific sarcomeric mutation replicated several cellular features 
observed in adult animals and patients carrying these mutations. Sar-
comeric disarray, one of the main pathological features of human HCM, 
was observed also in the early-stage embryonic cardiomyocytes. The 
myocardial response to sarcomeric gene mutations, in terms of gene 
expression changes, are quite preserved in the zebrafish, notwith-
standing the phylogenetic distance between the zebrafish and other 
mammal models [134]. One of the limitations of the zebrafish for 
modelling cardiac pathologies is its high cardiac tissue regeneration 
rate, allowing zebrafish to fully reconstitute its heart within several 
days, even if the damage is quite extended in the organ. This feature 
limits the use of the zebrafish as an optimal model for human cardio-
myopathies [135], as cardiac regeneration does not significantly occur 
in mammals. 
2.3. Larger animal models 
2.3.1. Transgenic HCM pigs 
Rodent models cannot fully reproduce the human HCM phenotype, 
showing several limitations that limit their use in cardiovascular 
research and cardiomyopathy modelling [125], due to the significant 
differences between rodent and human cardiac electrophysiological and 
mechanical properties. Besides the development of new larger animal 
models, such as transgenic rabbits, domestic pig [136,137] could 
represent an innovative tool to study molecular basis and 
patho-mechanisms of human HCM. In fact, considering its high resem-
blance to the human body in terms of cardiac anatomy, cardiovascular 
function, and electrophysiology [138,139], the domestic pig represents 
a useful model to study cardiovascular diseases (Fig. 2). Moreover, 
myosin isoform expression changes during cardiac development are 
equivalent in human and porcine fetuses [140,141], considering that 
both species are characterized by a gradual increase of ß-MyHC 
expression levels in the ventricles, and a concurrent reduction of 
α-MyHC expression in the second half of gestation [140,141]. Specif-
ically, ß-MyHC is the predominant isoform of the adult left ventricle and 
only 7–10 % of total ventricular myosin is α-MyHC in the adult human 
myocardium [142,143]; α-MyHC shows very similar expression levels in 
pig ventricles (about 10–12 %) [144]. In particular, considering the 
strong influence exerted by α- vs. ß-MyHC on the consequences of spe-
cific mutations on myosin function [125], mutations in murine α-MyHC 
(the predominant ventricular isoform in mice and rats) cannot precisely 
reproduce the functional abnormalities that are observed in the human 
ß-MyHC. Thus, the development of transgenic pigs carrying variants in 
the ventricular ß-MyHC is of utmost interest for cardiovascular research, 
since it will provide an informative model to evaluate their effects in 
animals model, faithfully replicating the cardiovascular physiology of 
humans. 
Montag and coworkers, using a TALEN-guided approach, mutated 
the MYH7 gene in the porcine genome through the insertion of the 
orthologous HCM-related mutation R723G. The early death observed in 
piglets suggested that the R723G mutation is responsible of a severe 
form of HCM, featuring early prenatal disease development [145]. 
Transgenic animals were characterized by signs of myocyte disarray and 
mechanical abnormalities of sarcomere function in cardiac tissue, that 
are likely suggestive of myofibrillar loss, one of the key features of HCM 
[146]. SD represents a common event among young patients carrying 
the same mutation (R723G into the MYH7 gene [147]). According to a 
recent hypothesis, many myosin missense HCM mutations cause the 
typical myocardial hypercontractility by shifting the equilibrium be-
tween the closed state of myosin heads (super-relaxed state) and their 
opened state (disordered-relaxed state, available for actin-interaction) 
towards the latter [148,149]. Anderson and coworkers generated 
R403Q minipigs carrying the heterozygous MYH7 R403Q mutation, 
which rapidly develop a cardiac phenotype with hypercontractility and 
hypertrophy, consistent with HCM. The hypercontractility displayed by 
this large HCM animal model was explained taking into account a 
consistent reduction in the percentage of super-relaxed state (SRX) of 
myosin in the porcine fibers. The administration of the cardiac myosin 
inhibitor mavacamten to the R403Q fibers from the pig model raised the 
percentage of the SRX in the porcine fibers by stabilizing their 
super-relaxed (SRX) folded state, consequently decreasing total tension 
measured in skinned porcine cardiac muscle fibers. In particular, 
mavacamten restored the percentage of SRX in R403Q porcine fibers 
back to the normal WT levels, suggesting an innovative way to modulate 
cardiac contractility at the molecular sarcomeric level [150]. 
2.3.2. Spontaneously-occurring HCM in cats 
Feline HCM represents an excellent natural model to study the patho- 
mechanisms of HCM and to identify potential novel targets for phar-
macological therapies, given the genotypic and phenotypic similarities 
to the human disease [151,152], the rapid progression of the disease, 
and the well-defined clinical endpoints. The cat model ideally over-
comes several limitations of rodent HCM models, providing an improved 
translation from animal studies to human clinical trials (Fig. 2). Feline 
HCM occurs spontaneously and with a relatively high frequently in some 
cat races. Disease presentation in cats is remarkably similar to that in 
humans [151,152], although more severe with mortality mainly driven 
by refractory heart failure due to severe left ventricular outflow 
obstruction. HCM can be identified casually in cats when a cardiac 
murmur is auscultated by the vet. After the diagnosis of HCM, most cats 
die from heart failure or sudden arrhythmic death, while a smaller part 
of them remains subclinical. Diagnostic tests in cats (e.g. plasma natri-
uretic peptide, radiography, electrocardiography, and echocardiogra-
phy) are also similar to those in HCM patients, as well therapeutic 
interventions [112], in particular β-blockers and diuretics. Among the 
overall feline population, the Maine Coon and Ragdoll cats are affected 
by HCM with a relatively high frequency, mainly driven by inbreeding 
practices. Known HCM-related mutations in Maine Coon and Ragdoll 
cats are located in the myosin binding protein-C gene, where a very 
limited number of pathogenic variants accounting for all cases of HCM 
[112]. While thousands of genetic variants have been identified in 
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humans and their pathogenicity have been deeply assessed [1], genetic 
studies in cats are partial and limited to single variants of the most 
involved sarcomeric genes (two variants in MYBPC3 and one variant in 
MYH7). In particular, the only two genetic variants associated with fe-
line HCM (p.A31P and p.R820W) in the MYBPC3 gene were identified 
with high frequency also in non-affected cats, suggesting a potential 
contribution of other genetic or environmental factors to the HCM 
phenotype, thus strengthening the doubt about their pathogenicity in 
heterozygotes [153]. The natural history of HCM in Maine Coon cats 
mimics that observed in humans and it is transmitted in an autosomal 
dominant way [154]. Kittleson and coworkers first described a colony of 
Maine Coon cats with an inherited, autosomal dominant form of HCM 
that mimics the human disease, replicating most of its common 
morphological characteristics [152]. Affected cats usually do not 
develop HCM before 6 months of age, overt disease develops between 6 
and 12 months of life, and severe HCM progression occurs between 2 
and 3 years of age. Maine Coon HCM cats show a gross asymmetric 
thickening of the LV wall, dynamic left ventricular outflow tract (LVOT) 
obstruction, disarray of cardiac fiber and fibrosis. Of note, notwith-
standing all aforementioned animal models represent an efficient tool to 
study different patho-mechanisms of human HCM, showing histologic 
features of the disease (hypertrophy of cardiomyocytes, diastolic 
disfunction, disarray, fibrosis, and increase in mass), only cats (sponta-
neously developing HCM) show left ventricular outflow tract obstruc-
tion (one of the clinical hallmarks of the disease). Considering that the 
clinical, pathological, and inheritable characteristics of feline HCM 
closely resemble those of human disease, cats may play an important 
role for understanding the pathophysiology of human HCM and for 
testing novel therapeutic pharmacological approaches, to be directly 
translated to patients [152]. Stern and coworkers employed cats with 
HCM and dynamic left ventricular outflow tract (LVOT) obstruction to 
evaluate whether a reduction in contractility mediated by mavacamten 
(MYK-461) could acutely eliminate systolic anterior motion (SAM) and 
LVOT obstruction [155]. In an exposure-dependent manner, treatment 
with mavacamten selectively reduced contractility and eliminated the 
systolic anterior motion of the mitral valve, thus relieving LVOT pres-
sure gradients. These results suggest that acute reduction in contractility 
exerted by mavacamten is sufficient to decrease LVOT obstruction, with 
a direct translation potential to human HCM treatment. 
Mavacamten was trialed in patients with obstructive HCM. A 
completed open label phase 2 study showed that mavacamten effec-
tively reduced LVOT gradients and obstructive symptoms in patients 
[156] with limited reduction of LV ejection fraction. These positive re-
sults were confirmed by the recently completed larger phase 3 study 
EXPLORER-HCM [157]. A pilot trial with mavacamten in 
non-obstructive patients (MAVERICK-HCM) showed a reduction of 
plasma pro-BNP and circulating cardiac TnI in the treatment arm [158]. 
Considering the paucity of data about the role of oxidative stress in 
the patho-mechanisms of HCM, Michalek and coworkers compared the 
oxidative state of cats with hypertrophic cardiomyopathy and healthy 
controls, focusing on the activity of specific enzymes, such as superoxide 
dismutase, catalase and glutathione peroxidase (GPx). Markers of 
increased oxidative stress were detected in feline blood serum; in 
particular, the activity of the scavenging enzyme superoxide dismutase 
was significantly reduced in the group of HCM cats. Similarly, the ac-
tivity of catalase that catalyzes the breakdown of H2O2, was consistently 
lower in animals at a preclinical stage of the disease [159] (Fig. 2). 
Gene transfer technology to overcome the limitations associated with 
transgenic animal models. 
Although transgenic mice represent an effective platform to study 
disease-associated patho-mechanisms, the phenotype expressed in this 
transgenic tools is the result of a combination between primary defects 
directly caused by the HCM causing mutation and the consecutive ad-
aptations provided by the animal to compensate that defect or the car-
diovascular remodeling that has occurred. For example, myofibrillar 
disarray displayed by many of the mouse models used to study human 
HCM [160] could be directly caused by the HCM mutant protein but can 
also represent a secondary consequence of cardiovascular remodeling 
necessary to counterbalance functional alterations caused by HCM 
mutant proteins. Therefore, transgenic animal models make difficult to 
discriminate primary defects caused by HCM mutant proteins from 
compensatory changes occurring during HCM pathogenesis in vivo. The 
application of gene targeting and gene transfer technology to adult 
cardiac myocytes in mice and primary culture provided a novel 
approach to directly screen effects of HCM mutant contractile proteins 
on the structure and function of adult cardiac muscle cells, gaining in-
sights into specific molecular mechanisms of HCM pathogenesis. 
Moreover, this approach allows to rapidly screen multiple mutations in 
contractile proteins without the cost and time related to the generation 
of multiple animal lines [161]. Rust and coworkers [162] described an 
efficient protocol that allows to transfected (through adenoviral gene 
transfer) adult rat cardiomyocytes to be maintained in primary culture 
for a period of 6–7 days, maintaining contractile protein isoform 
expression, stoichiometry, and force generation. As consequence, this 
protocol provides a stable “one-week window” in which to perform 
genetic manipulations of contractile proteins of the cardiac sarcomere. 
Moreover, Westfall and coworkers developed a tool through that 
adenoviral mediated gene transfer can be used to replace an endogenous 
protein with an expressed one. In particular, they substituted the 
endogenous cardiac TnI with expressed slow skeletal TnI, causing ab-
normalities in cardiomyocyte activity that can be directly associated to 
the specific manipulation of these TnI isoforms [163]. The expressed 
contractile protein within the cardiac muscle can then be assessed 
through different techniques as quantitative western blotting or high 
resolution immunofluorescence confocal microscopy, allowing to 
compare the expression of the mutant protein to endogenous proteins 
and the incorporation of the mutant protein in the myofilaments and its 
effects on sarcomere structure, respectively. However, the main limita-
tion associated to this approach is represented by the limited possibility 
to translate functional measurements from single cells to the whole 
organ [161]. 
2.4. Human iPSC as an innovative approach to model cardiomyopathies 
Time, cost, and species differences hamper the suitability of animal 
models for the study of HCM [164,106,165]. Importantly, differences in 
the electrophysiology and Ca2+ handling of cardiac myocytes signifi-
cantly restrict the role of murine models in cardiovascular research 
[166]. The functional evaluation of genetic alterations responsible for 
cardiac diseases (e.g. channelopathies) has been achieved by 
re-expressing the mutated proteins into heterologous systems in vitro. 
The molecular abnormalities investigated using heterologous expression 
systems were essential to understand the primary pathological mecha-
nisms of genetic diseases. However, heterologous expression systems are 
limited by the lack of a proper intracellular environment and the total 
absence of disease-associated cellular structural and functional remod-
eling [167]. The development of patient-derived induced pluripotent 
stem cells (iPSCs), which can be differentiated into functional car-
diomyocytes (CMs) in vitro, may play an increasing role in the study of 
disease mechanisms underpinning inherited genetic heart diseases 
[166] (Fig. 3). Frozen iPSCs remain available for subsequent differen-
tiation and, at variance with primary isolated CMs from adult hearts, 
harbor the ability to survive endlessly in culture [168]. Theoretically, 
any cell type can be obtained through directed differentiation from an 
iPSC line originated from somatic patient cells, allowing the researchers 
to model different inherited diseases, or to model the effects of a given 
mutation on different organs. iPSC-derived cells also show a huge po-
tential for drug research and development, as they represent a relatively 
endless source of material where pharmacological molecule testing can 
be extensively performed. Moreover, iPSCs represent an unequalled 
platform for regenerative medical interventions [166]. In particular, 
iPSCs are optimal for differentiation into cells such as cardiomyocytes, 
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which are difficult to be isolated from patients and are characterized by 
almost no regenerative potential in culture [169]. Therefore, the inte-
gration of genetic analyses and modeling disease with patient-specific 
iPSC-derived cells holds a huge potential to improve our knowledge of 
the genetic causes and the mechanisms of specific diseases. Since iPSC 
preserve the entire patient genetic profile, the system will help scientists 
in identifying the most appropriate pharmacological intervention to 
correct specific functional alterations with an individualized, 
precision-medicine approach [167]. Patient derived iPSCs could play a 
fundamental role in preclinical drug development and safety toxicology, 
overcoming limitations showed by recombinant cell lines or animal 
models, both susceptible to several shortcomings, as discussed above. In 
fact, hiPSC-CM are able to well reproduce the complexities of an adult 
human cardiomyocyte, thus pharmacological results from studies in 
hiPSC-CMs can be easily translated to patients. Interpersonal variability 
can be easily accounted by performing drug testing in different iPSC 
lines with a wide spectrum of genetic backgrounds. This may also allow 
evaluations of the individualized disease-related risk and of the indi-
vidual susceptibility to certain therapies [170]. Moreover, the applica-
tion of CRISPR/Cas9 system to WT hiPSC-CMs is fundamental to gain 
deeper insights into disease patho-mechanisms associated to a specific 
mutation. In fact, the insertion of a specific mutation in WT hiPSC-CMs 
through a gene editing method, as CRISPR/Cas9, allows to create an 
isogenic control that represents the benchmark to the control line. As 
consequence, potential differences (as in electro-physiological parame-
ters [171]) between control line and isogenic control can be directly 
correlated to the inserted mutation, thus evaluating its ability to dys-
regulate cardiomyocyte physiology. Considering the clear difference 
existing between human and rodent cardiomyocytes for what concern 
ion channel expression and biophysics [172], screening platforms based 
on WT hiPSC-CMs and suitable for medium- to high-throughput appli-
cation have been recently developed to perform the early phases of drug 
discovery and development [173–175]. Sala and coworkers described a 
protocol to dissociate 2D cell cultures of hPSC-CMs to small aggregates 
and single cells, plating them on multi-electrode Arrays (MEA) to record 
their spontaneous electrical activity as field potential (FP). As conse-
quence, perturbation of the FP waveform can be associated with changes 
in specific action potential phases [176], providing observations with 
respect to beating frequency, QT interval duration, and arrhythmic 
events. Compared with manual patch-clamp, MEA devices allow me-
dium- to high-throughput recordings of the electrical waveform signals 
generated by monolayers or small clusters of cardiomyocytes, thus 
supporting the standardization of the analysis of hPSC-CM FPs and 
improving data reproducibility. FP traces are extracted and then used to 
obtain QT interval values with specific settings. In particular, analysis of 
QT-RR relationship allows the researcher to gain insights in the evalu-
ation of the need and/or the effect of QT-interval corrections in diseased 
and WT hPSC lines, observing that hPSC-CMs carrying LQTS-causing 
mutations are characterized by prolonged QT intervals compared with 
WT controls. Moreover, while administration of a hERG activator results 
in shortening of the QT interval, treatment of hPSC-CMs with a hERG 
blocker results in QT interval prolongation [177]. This protocol devel-
oped by Sala and coworkers represents another confirmation of 
hiPSC-CMs efficiency in finely reproducing human pathologies in vitro, 
allowing specific disease-associated patho-mechanisms evaluation and 
drug-screening. 
2.4.1. iPSC-CMs to model human cardiomyopathies: pros and cons 
Despite many advantages, major limitations characterize this inno-
vative tool, such as the difficulties in obtaining a uniform population of 
completely reprogrammed iPSCs [178]. To overcome this restriction, 
Paull and coworkers described the development of fully automated and 
robotic processes for generating iPSC lines of high quality and consis-
tency, developing a modular, robotic platform for iPSc reprogramming 
Fig. 3. IPS cells as an invaluable research tool for disease modelling and drug screening. IPS (induced pluripotent stem cells) can overcome the limitations associated 
with the use of human surgical samples and transgenic animal models in preclinical research, representing an innovative tool for studying specific disease patho-
mechanisms and for drug discovery. Moreover, IPS cells can be employed to generate 3-D engineered heart tissues, overcoming the limitations associated to the 
standard two-dimensional (2-D) monolayer cell cultures, such as the possibility to efficiently measure contractile force, one of the most important parameters related 
to cardiac function that cannot be recorded in monolayers. Images from Pitoulis et al., 2019. 
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allowing automated, high-throughput conversion development of iPSCs 
and differentiated cells with negligible manual intervention. Moreover, 
this platform showed the ability to perform a pooled selection of poly-
clonal pluripotent cells, resulting in high-quality, stable iPSCs pop-
ulations. In particular, Paull and coworkers analyzed enriched samples 
using a gene expression panel covering pluripotency and germ-layer 
marker genes, employing negative selection against incompletely 
reprogrammed cells with an immunomagnetic bead separation device 
(MACS) to achieve a 26-fold enrichment of reprogrammed cells, thus 
separating full-reprogrammed iPSCs from incompletely-reprogrammed 
cells. Moreover, they observed that automation of the generation of 
pooled, polyclonal lines slowed to remove more than one-third of the 
variability that existed between manually selected lines, suggesting that 
a consistent portion of the variation observed between manually derived 
iPSC lines has purely technical origins that may obscure inherent 
genotypic differences [178]. 
Briefly, cell source, genetic background and age, reprogramming 
procedures, culturing conditions, and many other critical factors may 
influence the resulting iPSCs and introduce biases [166]. However, the 
most consisting limitation related to the use hiPSC-CMs as a source to 
model cardiomyopathies is that they have immature cellular features 
after differentiation, which more closely resemble the functional/mor-
phological features of fetal cardiomyocytes. Therefore, it is still 
controversial and debatable what stage of cardiac diseases can be 
effectively modelled by iPSC-CMs. Their immaturity encompasses a 
large spectrum of features arising from the expression of fetal genes 
[179,180], as well as electrophysiological signals and contractile prop-
erties that resemble fetal cells [181–183]. Moreover hiPSC-CMs are 
smaller in size, they show reduced electrical and contractile function, 
have disorganized sarcomeres and finally show an absence of t-tubules 
and a scarce sarcoplasmic reticulum organization [184]. Functional 
immaturity of iPSC-CMs was confirmed in an in vivo study, by trans-
planting hiPSC-CMs in a cardiac infarction model in primates [118]. The 
injected cells engrafted and regenerated the infarcted heart, although 
the issue of automaticity still remained manifesting in arrhythmogenic 
foci declining only over a 2–3 weeks period. Taken together, these 
findings suggested that maturation protocols for hiPSC-CMs are needed. 
In the last few years, many researchers have been exploring clues to 
foster maturation of hiPSC-CMs, with a wide range of methods such as 
growing cells on patterning scaffolds [185], or by employing 3D 
cell-alignment strategies [181], electrical and mechanical stimulation, 
co-cultures and custom growth media [186]. 
Among the strategies developed to improve hiPSC-CMs maturation, 
long-term culture on nanopatterned surfaces was described as an effi-
cient method, producing differentiated cardiomyocytes that more 
closely resemble human adult ventricular cardiomyocytes, with the 
development of transverse (T) tubules and the expression of sarcomere 
protein isoforms that are indicative of the tardive stages of maturation 
[182,187]. Pioner and coworkers described a custom-made experi-
mental setup for concomitant optical measurements of action potentials 
and calcium transients in hiPSC-CMs, which has been employed to 
identify a potential correlation between these parameters and specific 
time points of maturation (at 60, 75 and 90-day post-diff ;erentiation) in 
control cardiomyocytes. In particular, hiPSC-CMs were plated on 
hydrogel-based micropatterned substrates mimicking the extracellular 
matrix (stimulating cell alignment and elongation) and maintained in a 
long-term culture to evaluate potential developmental changes at later 
stages of maturation (days 60–75–90). At the tardive stages of the 
maturation process, single hiPSC-CMs showed prolonged action poten-
tial duration, increased calcium transient amplitude with shorter dura-
tion, characteristics that closely mirror those of human adult 
cardiomyocytes isolated from fresh ventricular surgical samples, 
demonstrating the efficiency of micropattern surfaces and long-term 
cultures in promoting hiPSC-CMs maturation [171]. hiPSC-CMs matu-
ration can be promoted also by cardiac-tissue-engineering approaches, 
organizing immature hiPSC-CMs into a 3D environment closely 
resembling the physiological cardiac tissue, in combination with cardiac 
fibroblasts [188]. Engineered heart tissues (EHTs) can be developed by 
casting myocytes and non-myocytes cardiac cells into a collagen 
hydrogel, where cardiomyocytes can be electrically and mechanically 
stimulated, thus improving their maturation. Vunjak-Novakovic and 
colleagues developed human EHTs bearing mature structural and 
functional properties, despite spontaneously beating, by incorporating a 
cell mixture composed of human dermal fibroblasts and early-stage 
hiPSC-CMs into an appropriately shaped fibrin hydrogel cast and then 
electrically stimulating the system for three weeks at increasing fre-
quencies (from 2 Hz to 6 Hz) [189]. The improved maturation level 
involved also the electrophysiological features, with mature EHTs 
showing a more negatively polarized resting membrane potential and an 
increased inward-rectifier potassium current density. Finally, EHTs 
developed by Vunjak-Novakovic and colleagues exhibited inotropic and 
lusitropic responses to β -adrenergic stimulation comparable to those 
observed in mature myocardium, confirming the efficiency of the 
method to generate mature human EHTs [189]. 
2.4.2. Pathophysiological and pharmacological insights from hiPSC-CM 
studies 
In the last years, various preclinical studies have described intra-
cellular Ca2+ handling abnormalities as the main determinants of 
electro-mechanical dysfunction in HCM. These observations are related 
to human ventricular cardiomyocytes isolated from human samples [47] 
or transgenic animal models. The central role of Ca2+ handling anom-
alies in the pathogenesis of HCM was confirmed by Lan et al., who 
generated functional patient-specific hiPSC-CMs from a ten-member 
family cohort harboring a HCM missense mutation (Arg663His) in the 
MYH7 gene. Besides replicating multiple features of the HCM pheno-
type, including cellular hypertrophy and arrhythmogenesis, patholog-
ical patient-specific iPSC-CMs confirmed that these phenotypic 
abnormalities were preceded by abnormalities in Ca2+ transients ki-
netics and increase of diastolic [Ca2+]I, efficiently elucidating that the 
dysregulation of Ca2+ cycling plays a main role as a cause of diastolic 
dysfunction and arrhythmogenesis in HCM [169]. These observations 
confirm the efficiency of iPSC technologies as novel methods to evaluate 
the connection between sarcomeric mutations and the development of 
overt HCM. hiPSC-CMs harboring the Arg663His mutation generated by 
Lan and coworkers replicated numerous features of the HCM phenotype 
in vitro: therefore, this innovative tool was also used as a screening 
platform to test the potential efficacy of a number of drugs at the 
single-cell level. Lan et al. exposed control and HCM iPSC-CMs to 
verapamil, a L-type Ca2+ channel blocker, and assessed whether phar-
macological reduction of Ca2+ entry prevented the onset of HCM-related 
phenotypic changes at cardiomyocyte level. Indeed, long-term exposure 
of pathological iPSC-CMs to verapamil markedly reduced all aspects of 
the HCM phenotype including Ca2+-handling abnormalities, arrhyth-
mogenicity and hypertrophy. Similar effects were obtained with nifed-
ipine and diltiazem, confirming that the observed effects were specific to 
Ca2+ channel inhibition. Extensive screening of other agents – currently 
employed to treat HCM – has also proved effectiveness: antiarrhythmic 
drugs that affect Na+ influx, such as ranolazine, lidocaine and mexiletine 
rescued normal beating in HCM iPSC-CMs counteracting the abnormal 
function of Na+/Ca2+ exchanger and limiting the influx of Ca2+ into the 
cardiomyocyte [169]. 
Calcium channel blockers (CCBs) such as diltiazem and verapamil 
are commonly used to treat HCM patients, even with life-long treatment 
(Table 1). Wu and collaborators tested the long-term effects of CCBs on 
human iPSC-CMs in terms of transcriptome changes [190]. After 14 days 
of treatment a transcriptomic approach was employed to assess the 
genes that were up- or down-regulated by CCBs administration. Verap-
amil, more than the other CCBs, downregulated cardiac 
contraction-related genes, as well as myofibril and sarcomere 
structure-related pathways. The downregulation of myofilament genes 
in HCM hearts may, at least in part, explain the efficacy of verapamil in 
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managing obstructive HCM. 
Another advantage of hiPSCs is the possibility to use genome-editing 
technologies to rapidly generate knock-out, knock-in, or reporter cell 
lines. CRISPR/Cas9 and TALENs allow introducing/removing specific 
mutations into the iPSCs genome [191,192] thus enabling the devel-
opment of isogenic controls. These approaches efficiently overcome the 
limitations related with the use of healthy mutation-negative family 
members as control subjects. Isogenic controls allow researchers to 
directly correlate the genetic defect with any observed phenotypic 
variations. As a consequence, the possibility to manipulate hiPSC lines 
through genome editing methods may play a significant role in the 
comprehension of specific patho-mechanisms of monogenic diseases 
such as HCM [193]. Although Troponin T mutations account for about 
6–8 % of patients with HCM [194], we demonstrated that Troponin T 
mutant mice represent excellent tools to study the pathophysiological 
mechanisms of human HCM, replicating many of the different pheno-
types that characterize human pathology [78]. Indeed, echocardio-
graphic measurements performed in WT, R92Q, and E163R revealed 
that both pathologic mice are characterized by a significantly increased 
septal thickness compared with WT mice, highlighting the presence of 
asymmetric left ventricular hypertrophy (LVH). Doppler studies of 
transmitral blood flow velocity demonstrated that in both mutant mice 
(more severely in R92Q), early LV filling was reduced and isovolumic LV 
relaxation time was prolonged, suggesting an impaired diastolic func-
tion. We then measured isometric force from intact left and right ven-
tricular trabeculae, observing that both E163R and R92Q trabeculae are 
characterized by prolonged twitch duration compared with WT [78]. To 
deeper analyze the E–C coupling process, intracellular Ca2+ measure-
ments were performed in isolated cardiomyocytes, showing that R92Q 
cardiomyocytes are characterized by a markedly prolonged intracellular 
Ca2+ transient decay compared with both WT and E163R car-
diomyocytes, at all stimulation frequencies tested. Diastolic [Ca2+]i was 
increased in both mutants but the largest change occurred in the R92Q 
model [78]. We then observed that both transgenic lines show 
arrhythmogenic activity compared to WT models at baseline, and this 
tendency to spontaneous events increased after the administration of 
isoproterenol. Western blot studies revealed that both transgenic hearts 
were characterized by an increased level of CaMKII autophosphor-
ylation and this augmentation was particularly evident in R92Q hearts 
compared with WT mice. We finally noticed an increased amount of 
intramyocardial fibrosis performing Picrosirius red staining on LV tissue 
sections in both R92Q and E163R hearts [78]. 
Wang and coworkers introduced the TnT-I79N [195] mutation into 
hiPSCs using CRISPR/Cas9, observing that this pathological line showed 
myofibril disarray and increased arrhythmogenic activity, thus con-
firming that the pro-arrhythmic AP changes are a direct consequence of 
HCM-linked TnT mutations in human CMs. In particular, AP triangula-
tion mediated by increased cytosolic Ca2+ binding was identified as a 
new mechanism of arrhythmogenesis [196]. The efficiency of 
genome-editing methods applied to hiPSC-CMs was confirmed also by 
Mosqueira et al., who used CRISPR/Cas9 editing to produce 11 variants 
of the HCM-causing mutation c.C9123T-MYH7 in three independent 
hiPSC lines [197]. The functional analysis of these lines showed a clear 
association between mutational load and the level of phenotypic and 
functional perturbation. Moreover, the effects of the mutations on 
mitochondrial function and on the transcriptome support the energy 
depletion theory of HCM pathogenesis, that is, the inefficient ATP uti-
lization by the disorganized sarcomeres increases the energetic demands 
from the cardiomyocyte [197]. The ability of hiPSC-CMs to efficiently 
reproduce the pathogenic feature of HCM was confirmed also by Toepfer 
and coworkers. They developed a MatLab algorithm called SarcTrack 
optimized for hiPSC-CMs, efficiently evaluating the mechanics of 
contraction at the level of the single sarcomere by monitoring different 
sarcomere parameters as sarcomere count and dynamic changes in 
sarcomere lenght (SL). In particular, SarcTrack analysis of hiPSC-CMs 
carrying the MYBPC3 mutation recapitulated the typical HCM 
phenotype, including cardiac hypercontractility and diminished relax-
ation. Moreover, through this algorithm, the application of the myosin 
allosteric modulator mavacamten (MYK-461) to mutant hiPSC-CMs 
abated the aforementioned pathological features, evidencing the po-
tential therapeutic efficacy of this molecule in human HCM patients 
[198]. The potential therapeutic effect of MYK-461 in HCM patients was 
analysed in greater depth by the same group in a more recent work, 
where restoration of the appropriate myosin super-relaxed state (SRX) 
balance by MYK-461 led to the normalization of the biophysical and 
metabolic abnormalities observed in mutant hiPSC-CMs. In this work, 
Toepfer and coworkers studied pathogenic MYH7 HCM mutations using 
patient-specific hiPSC-CMs, revealing that myosin conformations are 
central regulators of cardiomyocyte metabolism, balancing muscle work 
and metabolic costs. In fact, the alteration of myosin conformational 
state’s balance by myosin mutations has been noticed to play an 
important role for the direct perturbation in sarcomere efficiency and 
cellular homeostasis, resulting in increased contractility at the expense 
of higher energetic demands and impaired relaxation. Therefore, the 
restoration of the physiological myosin conformational state exerted by 
MYK-461 could act a relevant role in the therapeutic management of 
HCM [199]. 
2.5. Engineered heart tissues techniques to overcome the limitations of 2D 
systems in HCM modeling 
In vitro models of the heart are necessary to gain deeper insights into 
the mechanical and electrophysiological function of the organ in phys-
iological and pathological conditions. Moreover, they represent an 
efficient platform to screen the safety and efficacy of potential novel 
pharmaceutical molecules. Among the different tools used to study the 
heart in depth [200], cell culture is fundamental to understand multiple 
mechanisms responsible for cell behavior in vivo, uncovering different 
biomolecular processes by which cells assemble into functional tissues 
and organs and how this function can be altered in disease condition. In 
particular, two-dimensional (2D) conventional cell cultures, where cells 
adhere to a flat surface (typically represented by a petri dish of glass or 
polystyrene) providing mechanical support for the cells, have repre-
sented for a long time the most used cell culture system to maintain cells 
[201]. In fact, the ability of 2D systems to allows cells receiving a 
comparable amount of nutrients and growth factors present in the me-
dium, thus leading a homogenous growth and proliferation, makes 2D 
platforms attractive to biologists. However, under some circumstances 
2D methods cannot control the development of important features of the 
cell as the cell shape (determining biophysical cues affecting cell bio-
activities in vivo), thus failing to faithfully reproduce as the cell devel-
opment processes observed in the physiological environment in vivo as 
the associated cell bioactivities [201]. Nothwithstanding the various 
benefits related to their use in cardiovascular research, hiPSC-CMs are 
often used in single-cell assays, thus showing several limitations in the 
capability of representing in vivo cardiac environment. In particular, 
single cardiomyocytes lack relevant physiological features such as 
cell-to-cell interactions, the extracellular mileau and the tridimensional 
tissue organization. Moreover, single hiPSC-CMs reveal immature 
functional characteristics such as the reduced sarcomeric organization 
of myofilaments, one of the main features of mature cardiomyocytes. 
Bidimensional systems cannot generate contractile force, one of the 
most important parameters related to cardiac function; as a conse-
quence, cell shortening is often used as a proxy of contractility. 3D 
culture systems can overcome these limitations. In physiological con-
ditions, a highly elaborate 3D microenvironment directly coordinate cell 
bioactivities through different signals [202,203]. Moreover, essential 
cellular behaviors are affected by the distribution of cell-ECM and 
cell-cell interactions [204]. The development of 3D cell culture plat-
forms able to precisely replicate the complex cellular microenvironment 
opened the possibility to finely reproduce biochemical and biome-
chanical signals regulating cells bioactivities in vivo, thus accurately 
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modeling the in vivo interactions of tissues and organs [205]. In fact, 3D 
cell cultures are consistently different from standard 2D cultures for 
what concern cell-cell interaction, cellular mechanics, and nutrient ac-
cess, mimicking with high accuracy the in vivo environment and thus 
promoting proliferation, migration, matrix production, and stem cell 
differentiation [204]. The development of 3D culture systems is closely 
associated to the novel platform of engineered 3D heart tissues, over-
coming limitations proper of 2D tools [206] (Fig. 3). Tissue engineering 
represents a novel approach able to accurately replicate the myocardial 
niche, closely mimicking cell-cell and cell-matrix interaction and me-
chanics, thus improving the possibility of “in vitro” HCM modelling 
(Fig. 3). In particular, tissue engineering allows the generation of sur-
rogate three-dimensional (3-D) tissues, able to reproduce physiological 
organ function better than the classic two-dimensional (2-D) monolayer 
cell cultures [207]. The “traditional” tissue engineering approach con-
sists in building functional 3-D artificial heart tissues that can be placed 
onto the injured heart, such as the production of tissue matrixes that 
emulate the natural extracellular environment, consequently allowing 
cells to integrate into it and form an artificial tissue. The ability of 
engineered heart tissue to more faithfully reproduce human cardiac 
tissue than 2-D monolayer cell cultures can be explained considering 
that 3-D tissue allows communications of cells, creating contacts with 
surrounding cells in all directions, while cardiomyocytes cultured in 
monolayer cell cultures are plated on a rigid plastic surface that allows 
only side-to-side contacts with neighboring cells. Moreover, the 3-D 
environment stimulate differentiation of cardiac myocytes toward a 
completely mature phenotype, as detailed above, representing an 
important advantage for hiPSC-CMs differentiation [166,167]. 
Vunjak-Novakovic and colleagues developed a tool based on the 
pre-treatment of synthetic elastomeric scaffolds with cardiac fibroblasts 
(CFs), assuming that an environment of this kind could be helpful for 
cardiomyocyte, promoting their attachment, differentiation, and 
contractility, thereby stimulating the functional assembly of the engi-
neered cardiac constructs. Cells isolated from neonatal rat ventricles 
were prepared to form three distinct populations: rapidly plating cells 
identified as CFs, slowly plating cells identified as CMs, and unseparated 
initial population of cells (US). The cell fractions were seeded into pol-
yglycerol sebacate scaffolds using Matrigel™, separately (CM or CF), 
simultaneously (US), or sequentially (CF pre-treatment followed by CM 
culture, CF + CM) and cultured in spinner flasks. The CF + CM group 
was characterized by the highest amplitude of contraction and the 
lowest excitation threshold (ET), superior DNA content that contributed 
to the ET decrease, and higher glucose consumption rate (an index of 
metabolic activity), suggesting that presence of CF and their sequent 
application in cell co-culture improved the structural and contractile 
properties of engineered cardiac tissue. Moreover, cardiomyocytes 
belonging to CF + CM group (expressing cardiac markers as troponin I 
and sarcomeric α-actin) showed a parallel distribution, resembling 
organized architecture proper of the native heart, thereby enabling cells 
to a synchronous and vigorous contractile response. These data suggest 
that the co-culture of fibroblasts and cardiomyocytes improved the 
properties of the engineered heart tissue [189]. 
Many of the novel platforms developed to simulate the 3-D structure 
of human myocardium depend on the modulation of mechanical signals, 
facilitating the distribution and the alignment of cultured car-
diomyocytes in the framework of an exogenous extracellular matrix. In 
particular, cultured cardiomyocytes are embedded in a scaffolding ma-
trix (made of synthetic or natural polymeric materials) located within a 
structured platform with a well-defined shape, in order to correctly drive 
the structural development of the forming tissue [184,208]. While bio-
logical scaffolds do replicate more accurately the native cardiac 
extra-cellular matrix (ECM), synthetic scaffolds lead to more reproduc-
ible results, exhibiting stronger and more homogeneous mechanical 
properties. Among biological polymeric materials, liquid hydrogels such 
as collagen I [209–211] or matrigel [212] are often used [213] to form 
extracellular matrices in which freshly isolated cardiac cells will form 
appropriate cell-to-cell contacts and produce extracellular matrix on 
their own, consequently forming a mature-like tissue. These hydrogels 
also enact a protective role on isolated cells, preserving them from 
anoikis (i.e. cell death due to loss of cell-cell contacts) [214,143]. 
However, the main limitations associated to the use of engineered heart 
tissues (EHT) as tools to study HCM is that their force development is 
consistently smaller than human ventricular tissues [215]. Besides the 
application of EHT to disease modeling field, tissue engineering 
approach also represents a major improvement for preclinical drug 
development and safety toxicology. In fact, EHT allows researchers to 
evaluate the effects of drugs on all the main parameters of heart func-
tion, such as pace-making activity, force development, contraction and 
relaxation kinetics, faithfully replicating cardiac physiology. 
Breckwoldt and coworkers developed a protocol to generate fibrin- 
based EHTs featured by a great resemblance to human heart tissue. In 
particular, hiPSC-CMs incorporated in the EHTs are characterized by 
electrophysiological properties closely similar to those of human adult 
CMs, representing a clear advantage over 2D systems [206]. Mannhardt 
and coworkers developed a hiPSC-EHT model, evaluating the 
morphology and function of engineered 3D heart muscle strips and their 
suitability for drug screening, particularly focusing on the contractile 
force of hiPSC-CMs within the hiPSC-EHTs. hiPSC-CM in EHT format 
demonstrated a high degree of similarity with native human heart tissue. 
Indeed, they observed that the EHT format supports excellent heart 
tissue formation and promotes an efficient morphological maturation of 
hiPSC-CMs [170]. Eschenhagen and colleagues described the generation 
of 3D force-generating engineered heart tissues from hiPSC-CM, evalu-
ating their physiological and pharmacological properties. hiPSC-CMs in 
EHTs showed well-developed sarcomeric organization and alignment, 
demonstrating a high degree of similarity between hiPSC-CM in EHT 
format and native human heart tissue, highlighting their informative 
role in preclinical drug screening and disease modeling. In particular, 
while cardiomyocytes cultured in 2D systems are characterized by poor 
sarcomeric organization and less cellular alignment, cardiomyocytes in 
EHTs showed a highly organized sarcomere structure, starting to beat 
spontaneously 10–14 days after casting. Video-optical recording was 
performed to investigate pacemaker mechanisms in hiPSC-EHTs, 
showing that five different compounds (ivabradine, ryanodine, 
SEA-0400, isoprenaline, TTX) affected the membrane clock in 
hiPSC-EHTs increasing or decreasing the beating rate, thereby demon-
strating the ability of hiPSC-CMs in 3D force-generating engineered 
heart tissues to react to pharmaceutical stimulations, faithfully repro-
ducing the responses of native human heart tissue. Moreover, 
hiPSC-EHTs were tested for response to positive and negative inotropic 
modulators (Ca2+, ouabain, isoprenaline, ryanodine, verapamil) under 
rate control (1–2 Hz), showing significant inotropic modifications for all 
compounds evaluated: while Ca2+ and verapamil regulated force 
without affecting contraction kinetics, isoprenaline mediated an in-
crease in force development associated to characteristic positive lusi-
tropic effect. Finally, Ryanodine showed biphasic responses typical of 
the native human heart, reducing or increasing force development at 
low (0.3 mM) and high (10 mM) concentrations respectively [170]. 
Such an approach aimed at disease modeling was confirmed also by 
Cashman and coworkers, who developed the first 3D functional hECT 
model of HCM, using iPSC-hECTs from BRAF-mutant cells collected 
from a patient with cardiofacio-cutaneous syndrome (CFCS) and evi-
dence of HCM. Mutant engineered tissues showed increased car-
diomyocyte size, higher increased contraction and relaxation rates 
associated with an evident arrhythmogenic substrate [216]. Among the 
different approaches to produce 3D EHTs, the “CardioSlice’’ method 
deserves a particular mention. By developing this method, 
Valls-Margarit and coworkers created innovative cardiac macro-tissues 
from hiPSCs. Specifically, hiPSC-derived cardiomyocytes and human 
fibroblasts were placed into large 3D porous scaffolds and were sub-
jected to a constant electrical pacing for 2 weeks in culture, thus pro-
moting the emergence of myocardial tissue-like properties. Continuous 
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electrical stimulation markedly improved electromechanical coupling, 
enhancing structural and functional maturation of cardiac constructs at 
the tissue level but resulting in minor improvements in cardiomyocyte 
maturation. In fact, focusing on single cell level, cardiomyocytes laying 
within these scaffolds showed evident features of improved cell matu-
ration compared with cardiomyocytes cultured under 2D conditions, 
though features of immaturity were still present, such as the expression 
of a fetal-like ion channel profile [217] (Fig. 3). 
3. Conclusions and development 
This review summarizes the different available platforms used in the 
recent years to gain insights into the patho-mechanisms of HCM and to 
screen novel pharmaceutical drugs before they undergo clinical trials. 
Although human surgical samples show a very high translational value, 
they are characterized by several limitations, such as the scarce avail-
ability of surgical material and the wide genetic heterogeneity among 
patients [78]. Moreover, surgical human tissue models are representa-
tive of a tardive stage of HCM, thus making it difficult to discern be-
tween mutation-related induced primary mechanisms and secondary 
and tertiary mechanisms caused by myocardial adverse remodeling and 
disease progression. To overcome restrictions associated to the use of 
surgical human samples into basic research and drug screening, different 
types of animal models have been developed through the years, with 
inbred strains overwhelming genetic background differences and 
extensive breeding capacity guaranteeing a wide availability of vital 
organs to be deeply examined. Transgenic mouse models represent the 
starting platform to gain insights into the molecular basis of HCM, 
making it possible to explore different patho-mechanisms of the disease 
and then providing deeper comprehension into the potential novel 
pharmaceutical strategies for the prevention or regression of HCM. 
However, various limitations of rodent models, mainly due to species 
differences (e.g., anatomy, physiology, metabolic rate, lifespan, and 
response to treatment) can limit the predictive value of transgenic ani-
mals in translating novel knowledge to humans [112]. The aforemen-
tioned restrictions suggested the need to develop larger preclinical 
models closer resembling human HCM pathophysiology [112]. Trans-
genic rabbits were used as models to study HCM [116] for their ability to 
accurately reflect the human system combined with their larger size as 
compared with mice. However, among larger animal models, pigs and 
feline surely play a leading role for pre-clinical research. In fact, given 
the genotypic and phenotypic similarities to humans, including cardiac 
anatomy, cardiovascular function, and electrophysiology [136–139, 
151,152], feline and pigs represent a novel and informative platform to 
study the patho-mechanisms of human HCM and thus to test novel 
molecules. In particular, feline HCM represents an excellent natural 
model to study the patho-mechanisms of the disease and play an 
important role for drug screening. The restrictions affecting the use of 
transgenic models in translational research and pharmacological testing, 
such as time, cost and species differences [164,106,165] can be sur-
mounted by parallel implementation of patient-derived hiPSC-CMs. This 
innovative tool, supplying a potentially unlimited amount of human 
cells preserving the entire genome of the patient, may represent an 
exciting new approach for modelling inherited heart diseases as HCM 
[166] and an important way to screen and test novel drugs for HCM 
therapy. 
Application of gene editing approaches as CRISPR/Cas9 system to 
WT hiPSC-CMs is fundamental to analyze in detail disease patho- 
mechanisms associated to a specific mutation. In fact, the insertion of 
a specific mutation in WT hiPSC-CMs through CRISPR/Cas9 results in an 
isogenic positive control, allowing to directly correlate potential dif-
ferences (as in electro-physiological parameters) between control line 
and isogenic control to the inserted mutation [171], thus evaluating its 
ability to affect cardiomyocyte physiology. In vitro gene editing ap-
proaches may also be used as a proof of concept for in vivo therapies 
aimed to “cure”, rather than alleviate, HCM symptoms and risks. Indeed, 
current pharmacological strategies for HCM cited in this review can 
weaken disease-associated symptoms, slowing down disease progres-
sion, but cannot durably correct the genetic, hereditary defect at the 
base of HCM. Among the different available tools (antisense oligonu-
cleotides, RNA interference molecules or wild-type cDNA sequences) 
able to edit DNA in gene therapy approaches, the most used is repre-
sented by clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9, often combined with Adeno-associated virus (AAV) 
delivery. The ability to transduce terminally differentiated cells and 
long-lasting gene expression makes the use of AAV attractive for gene 
therapy [218]. Many reports recently described the application of 
CRISPR/Cas9 system to hiPSC technique, reporting favorably creation of 
HCM models or genetic correction in HCM hiPSC [196,197,219]. In 
particular, Jehuda and coworkers [219] described the correction of the 
PRKAG2 gene mutation through CRISPR/Cas9 technology in the 
iPSC-CMs from a patient affected by HCM. Comparing the patient’s 
iPSC-CMs and the resulting isogenic control created by the application of 
CRISPR/Cas9 technology, the authors observed that the 
electro-physiological (delayed afterdepolarizations, triggered arrhyth-
mias, and augmented beat rate variability) and structural (car-
diomyocyte hypertrophy) abnormalities exhibited by PRKAG2-mutated 
iPSC-CMs were abolished, suggesting an efficient correction of the ge-
netic defect responsible of HCM exerted by CRISPR/Cas9 system in the 
patient’s iPSC-CMs [219]. Another sector where CRISPR/Cas9 genome 
editing technique found both acclaim and concern is represented by the 
human germline therapy, since different reports described efficient 
application of CRISPR/Cas9 to human embryos [220–222]. For instance, 
Ma and coworkers reported the successful correction of germline mu-
tations mediated by the activation of germline-specific DNA repair 
response in male patient with a familial history of HCM caused by a 
deletion in the MYBPC3 gene [221]. 
According to a recent report [223], telomere shortening may repre-
sent a hallmark of genetically induced cardiomyopathies, such as HCM. 
Sharifi-Sanjani and coworkers investigated telomere length (TL) in 
cardiomyocytes isolated from human cardiac tissues procured from 2 
separate patient groups: 37 patients with end-stage HF transplant 
(including 17 HCM patients) and 26 nonfailing donors with no history of 
HF (NFDs). In particular, the authors observed that TL is significantly 
shorter in HCM hearts compared to healthy individuals, promoting TL as 
a specific feature oh HCM cardiomyocytes. Moreover, cells isolated from 
patients with reduced ejection fraction showed the shortest telomeric 
lengths, suggesting a potential link between ejection fraction and the 
severity of the disease [223]. Considering the abnormal TL observed in 
HCM cardiomyocytes, novel therapeutic strategies could be based on 
drugs/tools able to restore the physiological telomere length, thus 
potentially ameliorating abnormalites associated to HCM mutations. 
The impressive progression in these fields opens open new horizons for 
HCM therapies. 
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